1	Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin
2	A.M. Turner ¹ , L. Li ¹ , I.R. Monk ¹ , J.Y.H. Lee ^{1,2} , D.J. Ingle ¹ , S. Portelli ^{3,4} , N.L. Sherry ^{1,5,6} , N. Isles ¹ , T.
3	Seemann ^{1,5,7} , L.K. Sharkey ¹ , C.J. Walsh ¹ , G.E. Reid ^{8,9,10} , S. Nie ¹¹ , B.A. Eijkelkamp ¹² , N.E.
4	Holmes ^{6,13} , B. Collis ⁶ , S. Vogrin ^{6,14} , A. Hiergeist ¹⁵ , D. Weber ¹⁶ , A. Gessner ¹⁵ , E. Holler ¹⁴ , D.B.
5	Ascher ^{3,4} , S. Duchene ¹ , N.E. Scott ¹ , T.P. Stinear ^{1,7} , J.C. Kwong ^{1,6} , C.L. Gorrie ^{1,5,7} *, B.P.
6	Howden ^{1,5,6,7} * [†] and G.P. Carter ¹ * [†]
7	¹ Department of Microbiology and Immunology, The University of Melbourne at The Peter
8	Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
9	² Department of Infectious Diseases, Monash Health, Clayton, VIC, Australia.
10	³ Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute,
11	Melbourne, Victoria, Australia.
12	⁴ SCMB, The University of Queensland, Saint Lucia Campus, Saint Lucia, Queensland, Australia.
13	⁵ Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and
14	Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and
15	Immunity, Melbourne, VIC, Australia.
16	⁶ Department of Infectious Diseases & Immunology, Austin Health, Melbourne, VIC, Australia.
17	⁷ Centre for Pathogen Genomics, The University of Melbourne, Melbourne, VIC, Australia.
18	⁸ School of Chemistry, The University of Melbourne, Melbourne, VIC, Australia.
19	⁹ Department of Biochemistry and Pharmacology, The University of Melbourne, Melbourne,
20	VIC, Australia.
21	¹⁰ Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne,
22	Melbourne, VIC, Australia.
23	¹¹ Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and
24	Bionte chaplegy lestitute retacilizing situas situas for the bay see revision bay some Alla substration of the substration of

- ¹²Molecular Sciences and Technology, College of Science and Engineering, Flinders University,
- 26 Adelaide, SA, Australia.
- ¹³Department of Infectious Diseases, The University of Melbourne at The Peter Doherty
- 28 Institute for Infection and Immunity, Melbourne, VIC, Australia.
- ¹⁴Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
- 30 ¹⁵Institute of Clinical Microbiology and Hygiene, University Medical Center, Regensburg,
- 31 Germany.
- ¹⁶Department of Internal Medicine III, Hematology and Medical Oncology, University Medical
- 33 Center, Regensburg, Germany.
- 34 *These authors supervised this work equally.
- 35 **+Corresponding authors:** <u>glen.carter@unimelb.edu.au</u>, <u>bhowden@unimelb.edu.au</u>
- 36

37 Abstract

38 Multidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium 39 (VREfm) are a critical threat to human health. Daptomycin is a last-resort antibiotic for VREfm infections with a novel mode-of-action, but for which resistance has surprisingly been widely 40 41 reported but unexplained. Here we show that rifaximin, an unrelated antibiotic used 42 prophylactically to prevent hepatic encephalopathy in liver disease patients, causes cross-43 resistance to daptomycin in VREfm. Amino acid changes arising within the bacterial RNA polymerase in response to rifaximin exposure cause upregulation of a previously 44 45 uncharacterised operon (prdRAB) that leads to cell membrane remodelling and cross-46 resistance to daptomycin through reduced binding of the antibiotic. Alarmingly, VREfm with 47 these mutations are spread globally, making this a major mechanism of resistance. Rifaximin 48 has been considered 'low-risk' for antibiotic resistance development. Our study shows this

49 assumption is flawed and widespread rifaximin use, particularly in patients with liver cirrhosis, 50 may be compromising the clinical use of daptomycin, a major last-resort intervention for 51 multidrug-resistant pathogens. These findings demonstrate how unanticipated antibiotic 52 cross-resistance can undermine global strategies designed to preserve the clinical use of 53 critical antibiotics.

- 54
- 55 Main

Antimicrobial resistance (AMR) is one of the greatest public health threats, with 1.27 million 56 57 deaths being directly attributable to bacterial AMR in 2019¹. The magnitude of this threat is therefore similar to that of malaria (558,000 global deaths in 2019)², HIV (690,000 deaths in 58 2019)³, and diabetes mellitus (1.5 million deaths in 2019)⁴. Infections caused by multidrug-59 60 and extensively-drug resistant pathogens are of particular clinical concern since they are 61 associated with frequent treatment failure and high-rates of morbidity and mortality. The 62 preservation of last-resort antibiotics that can be used to treat these formidable pathogens is of critical importance. 63

64

65 Enterococcus faecium is one such formidable pathogen. It is a commensal of the human 66 gastrointestinal tract that has emerged as a major cause of nosocomial infections⁵. The 67 intrinsic antibiotic resistance of hospital-associated clones coupled with their ability to rapidly acquire additional antibiotic resistance genes makes *E. faecium* infections increasingly difficult 68 69 to treat⁶. In particular, strains resistant to vancomycin, the first-line antibiotic for invasive 70 infections, have emerged and disseminated globally due to the acquisition of transferable van resistance genes⁷. Consequently, *E. faecium*, which is one of the ESKAPE⁸ pathogens, has been 71 72 recognised by the World Health Organization (WHO) as a 'high priority' bacterial pathogen⁹.

-	2
	-
	-

The lipopeptide daptomycin is a WHO designated last-resort antibiotic that is used 'off-label' to treat severe vancomycin-resistant *E. faecium* (VREfm) infections¹⁰. The increasing reports of daptomycin-resistant VREfm are of great clinical concern. Daptomycin resistance in clinical VREfm has been associated with the presence of specific amino acid changes in the regulatory systems LiaFSR/LiaXYZ and cardiolipin synthase Cls^{11–13}. However, many daptomycin-resistant VREfm contain wild-type (WT) *liaFSR/liaXYZ* and *cls* alleles, indicating other unknown molecular pathways are involved^{12,14,15}.

81

In Australia, high rates (15%) of daptomycin-resistant VREfm were recently reported¹⁶, but the 82 83 data were not epidemiologically robust and the specific genetic determinants leading to 84 resistance were not defined using molecular techniques. Accordingly, we undertook a 85 combined genomic and phenotypic analysis to investigate the daptomycin resistance 86 mechanisms in VREfm. Here we show that daptomycin resistance is linked with the presence 87 of specific mutations within the *rpoB* gene, with resistance emerging *de novo* in *E. faecium* following exposure to rifaximin, a commonly prescribed antibiotic used prophylactically to 88 prevent hepatic encephalopathy in liver disease patients¹⁷. The emergence of these 89 90 daptomycin-associated rpoB mutations leads to transcriptional reprogramming in VREfm and 91 daptomycin resistance via a mechanism that is independent of previously described systems, 92 such as the *lia* operons or *cls*. Instead, the daptomycin-associated *rpoB* mutations cause 93 upregulation of a previously uncharacterised genetic locus that results in cell membrane 94 remodelling, which ultimately increases the cell surface charge and reduces daptomycin 95 binding. Our work has uncovered a major new mechanism of daptomycin resistance in VREfm

96 and identified rifaximin, an antibiotic considered to be low-risk for the emergence of bacterial

97 AMR¹⁸, as an important driver of last-resort antibiotic resistance.

- 98
- 99 Results

100 Daptomycin resistance in Australian VREfm is polygenic and does not correlate with known

101 resistance determinants.

102 Daptomycin susceptibility testing was performed on VREfm isolated during two unbiased 103 state-wide 'snapshot' studies undertaken for month-long periods in 2015 (n=294) and 2018 104 (n=423) in Victoria, Australia. The proportion of daptomycin-resistant isolates was 16.6% (n=49) in 2015 and 15.3% (n=65) in 2018. Given the high-rate of resistance observed, we 105 106 expanded the study to include VREfm isolated in 2017 (n=108) and 2018 (n=173) as part of 107 the 'Controlling Superbugs' study^{19,20}, with 28.4% (n=80) of these isolates being resistant to 108 daptomycin. Overall, we observed 194 (19.4%) daptomycin-resistant VREfm isolates, 109 indicating a very high prevalence of daptomycin resistance in Victoria, Australia.

110

111 To investigate the relationship between daptomycin-resistant and daptomycin-susceptible VREfm, a maximum-likelihood phylogeny was inferred from an alignment of 6,574 core 112 113 genome single nucleotide polymorphisms (SNPs) (n=1000; 998 study isolates and two 114 controls) (Supplementary Figure 1). In silico multi-locus sequence typing identified 36 sequence types (STs) within the 1000 isolates; 30 of these STs included at least one of the 115 116 daptomycin-resistant VREfm. Daptomycin resistance was polyphyletic, with several distinct 117 clades. The largest clade (ST203) of daptomycin-resistant strains, accounted for 41.2% of 118 resistant isolates (n=80 of 194) and consisted of a predominant clone during our sampling 119 timeframe (2015 to 2018), suggestive of an expanding daptomycin-resistant lineage. The

other predominant STs (ST80, ST796, ST1421, and ST1424) consisted of several groups of
 resistant isolates that did not cluster based on tree structure. The presence of daptomycin resistant isolates in distinct genetic backgrounds suggested daptomycin resistance has arisen
 independently in VREfm on multiple occasions.

124

We next sought to determine the genetic determinants leading to daptomycin resistance in Australian VREfm. We systematically screened VREfm genomes for mutations in the regulatory genes *liaFSR*, *liaXYZ*, *yycFG* (*walKR*), cardiolipin synthase (*cls*), and the division site tropomyosin locus (*divIVA*), all previously linked to daptomycin resistance^{10,11,21}. Unexpectedly, there were no significant associations with daptomycin resistance and mutations in these loci (Supplementary Table 1).

131

132 The S491F substitution in RpoB is a novel mediator of daptomycin resistance in VREfm.

133 To identify the loci linked with daptomycin resistance, we performed a genome-wide 134 association study (GWAS) with 1000 E. faecium isolates (Figure 1A). This analysis identified 135 142 mutations (in 73 genes) significantly ($P < 1x10^{-10}$) associated with daptomycin resistance (as a binary variable with a breakpoint of 8 mg L⁻¹). The top five significant amino acid 136 137 substitutions were (i) I274S in an uncharacterised ABC efflux protein (*P*=7.44x10⁻¹⁵), (ii) G71S 138 in an uncharacterised permease protein (P=7.77x10⁻¹⁴), (iii) V288L in a mannitol dehydrogenase protein (P=6.08x10⁻¹²), (iv) S491F in RpoB, which is the RNA polymerase ß 139 subunit (P=1.57x10⁻¹³), and (v) T634K in RpoC, which is the RNA polymerase ß' subunit 140 141 (P=4.40x10⁻¹¹).

143 To test the contribution of these amino acid substitutions on daptomycin resistance we 144 engineered each mutation into a clinical daptomycin-susceptible strain of VREfm (ST796). 145 Introduction of the I274S substitution in the ABC efflux protein, G71S substitution in the 146 permease protein, V288L substitution in the mannitol dehydrogenase protein, or T634K 147 substitution within RpoC had no impact on daptomycin susceptibility. However, introduction 148 of the S491F substitution within RpoB resulted in a daptomycin-resistant phenotype (4-fold 149 increase in daptomycin MIC, from 2 mg L⁻¹ to 8 mg L⁻¹). Interestingly, every clinical strain 150 harbouring the RpoB S491F substitution (n=105, spanning different *E. faecium* genotypes) also 151 contained the RpoC T634K substitution (n=105), with no strains containing the RpoC T634K in 152 isolation. Introduction of the RpoC T634K substitution into the RpoB S491F mutant 153 background did not affect daptomycin susceptibility (MIC still 8 mg L⁻¹), suggesting this 154 mutation does not play a direct role in the daptomycin resistance phenotype and instead may 155 be compensatory for negative fitness effects associated with the RpoB S491F substitution. In 156 a competition assay (WT versus RpoB S491F or WT versus RpoB S491F/RpoC T634K), the RpoB 157 S491F substitution posed a substantial fitness cost, with a significant (P<0.0001) shift to the 158 WT population (Supplementary Figure 2). However, in the double RpoB S491F/RpoC T634K 159 mutant the population dynamics remained stable, with no significant differences compared 160 to inoculation observed (Supplementary Figure 2). These data suggest the RpoC T634K 161 substitution is compensatory for the negative fitness effects of RpoB S491F, a hypothesis consistent with studies in Mycobacterium tuberculosis²² and Escherichia coli²³. 162

163

Different substitutions within the rifampicin resistance determining region of RpoB result in
 daptomycin resistance in VREfm.

We next assessed if other RpoB substitutions were associated with daptomycin resistance 166 167 (Figure 1B). We observed resistance in 81.3% of VREfm strains (n=16) with a G482D 168 substitution and 83.3% of VREfm strains (n=12) with a H486Y substitution. Isolates harbouring 169 these mutations were spread across the phylogenetic tree, indicative of multiple independent 170 acquisitions (Figure 1C). No putative compensatory mutations in the RNA polymerase genes 171 were identified. Clonal expansion was also observed for a dominant, daptomycin-resistant 172 clone (ST203) containing the S491F substitution. Daptomycin-resistant isolates from this 173 ST203 lineage were identified across 10 geographically distinct hospital networks, indicating 174 they were not part of a singular hospital outbreak (Supplementary Figure 3).

175

The G482D, H486Y, and S491F substitutions were located within the predicted rifampicinresistance determining region (RRDR) of RpoB (spanning amino acids 467 to 493). Rifampicin susceptibility testing (rifampicin being a marker of rifamycin resistance²⁴) confirmed all isolates had high-level rifampicin resistance (n=169, median MIC 256 mg L⁻¹), while control isolates containing the WT RRDR displayed a median MIC of 8 mg L⁻¹ (n=169, Supplementary Figure 4).

182

To test if the G482D and H486Y substitutions in RpoB also led to rifamycin and daptomycin resistance we engineered isogenic mutants with these substitutions in our rifamycinsusceptible, daptomycin-susceptible, clinical strain of VREfm (ST796). Introduction of the G482D, H486Y, or S491F RpoB substitutions resulted in a 7-fold decrease in rifampicin susceptibility compared to the WT strain, leading to high-level rifampicin resistance (>512 mg L⁻¹) (Figure 1D). The introduction of the G482D or H486Y RpoB substitutions also resulted in a daptomycin-resistant phenotype (4-fold increase in daptomycin MIC, from 2 mg L⁻¹ to 8 mg L⁻¹

¹) (Figure 1E). Reverse allelic exchange with the WT *rpoB* allele resulted in susceptibility to
 rifampicin (MIC of 4 mg L⁻¹) and daptomycin (MIC of 2 mg L⁻¹), confirming that G482D, H486Y,
 and S491F caused rifamycin resistance and daptomycin cross-resistance.

193

194 The G482D, H486Y, and S491F RpoB substitutions are common in international VREfm 195 strains.

196 To determine if the RpoB substitutions associated with daptomycin resistance observed in 197 Australian VREfm were representative of other *E. faecium* globally, we analysed publicly 198 available VREfm sequence data (n=3,476 international and n=1,000 Australian) (Figure 2A). 199 The majority (n=3,378) of these VREfm were healthcare-associated, with 98 isolates from 200 animal origin. Of all the isolates analysed, 630 (14.1%) carried an amino acid substitution in 201 the RRDR of RpoB, with the S491F substitution being the most common, present in 77.9% 202 (n=461) of isolates with a RRDR RpoB substitution (Figure 2B). The S491F substitution was 203 identified in isolates from 20 countries and across 21 different STs (Figure 2B and 204 Supplementary Figure 5A). Importantly, five VREfm (from three genetic backgrounds and four 205 countries) harbouring the S491F substitution also contained cfr(B) (n=4) or poxtA (n=1) 206 linezolid resistance genes, suggesting near pan-resistant strains of VREfm have emerged. The 207 G482D and H486Y substitutions were also commonly identified, found in 6.8% (n=43) and 208 11.6% (n=73) of strains with the RpoB substitution, respectively. The G482D and H486Y 209 substitutions were also observed globally (7 and 10 countries, respectively) and across 210 different STs (9 and 22, respectively) (Figure 2B and Supplementary Figure 5A). These data 211 indicated the RpoB substitutions conferring resistance to rifamycins and cross-resistance to 212 daptomycin are globally prevalent. We also observed a significant association between RRDR 213 RpoB substitutions and healthcare-associated VREfm (P<0.001; Fisher's exact test)

(Supplementary Figure 5B)²⁵, suggesting the identified RpoB substitutions are enriched within
 the healthcare setting.

216

Phylodynamics show the S491F RpoB substitution emerged within the VREfm population in the same period as the clinical approval of rifaximin.

219 We used phylodynamic analyses to estimate the emergence date of VREfm harbouring the 220 S491F substitution globally. Within the genomes of Australian VREfm isolates, we observed 221 the expansion of a dominant ST203 clone from 2015 to 2018 that carried the S491F 222 substitution (Figure 1C). Since this clone comprised VREfm carrying the vanA resistance 223 operon, we genome sequenced all historical vanA-VREfm from our public health laboratory 224 (n=229), which consisted of every vanA-VREfm isolate collected from 2003 to 2014, to 225 increase the potential to detect a molecular clock signal. Using comparative genomics, we 226 contextualised all Australian isolates (n=1,229) with the international data (n=3,476) and 227 identified three distinct clusters containing the RpoB S491F substitution (Figure 2C). The same 228 ST203 clone formed the largest cluster (Cluster 1; n=219 taxa), consisting of isolates from 229 Australia and United Kingdom. Cluster 2 (n=85 taxa) consisted of ST80 and ST78 isolates from 230 Australia, Europe, South America, the United Kingdom, and the United States while Cluster 3 231 (n=68 taxa) consisted of ST80 isolates from Australia, Europe, and the United Kingdom.

232

To model the evolutionary trajectories of these clusters, we used core-genome SNP diversity and year of isolation (Figure 2D and Supplementary Figure 6). The substitution rate (the number of expected nucleotide substitutions per site per year) was consistent with other estimates for healthcare-associated VREfm^{25–28} (Figure 2D). The year of emergence for the most recent common ancestor (MRCA) of each cluster with S491F was around 2006 (Figure

2D), a time period that coincides with the first clinical use of rifaximin. Since rifampicin was 238 approved for clinical use in the United States in 1971²⁹, several decades before the estimated 239 240 emergence of the S491F-containing VREfm strains, we considered this rifamycin unlikely to 241 have played a major role in the spread of resistance. Analysis of the three maximum clade 242 credibility (MCC) trees (Figure 2D) indicated each E. faecium lineage has continued to expand 243 since its emergence, consistent with the growing use of rifaximin globally, in particular since 2010 when it was approved for the prevention of hepatic encephalopathy¹⁷ (Figure 2D-E). It 244 245 is also noteworthy that in all three VREfm clusters, the S491F substitution has been stably 246 maintained after its acquisition, suggestive of on-going selective pressure acting on the bacterial population, as rpoB mutations usually carry a fitness cost (Supplementary Figure 7A-247 C)²². These data show the S491F substitution emerged within the VREfm population on at least 248 249 three occasions since the early 2000s, with the predicted dates of emergence closely 250 correlated with the clinical introduction of rifaximin.

251

Patients receiving rifaximin are more likely to carry VREfm with daptomycin resistance RpoB substitutions than patients that have not received rifaximin.

254 Rifaximin is a non-absorbable oral agent with direct antimicrobial activity in the 255 gastrointestinal tract, predominately prescribed to prevent recurrent hepatic encephalopathy 256 in patients with liver cirrhosis^{17,30}. This patient cohort is high-risk for VREfm gastrointestinal 257 colonisation³¹. Since the Bayesian phylodynamic analyses highlighted a correlation between 258 the S491F RpoB substitution in VREfm and use of rifaximin, we hypothesised rifaximin use in 259 VREfm colonised patients may be associated with the presence of substitutions in RpoB and, 260 therefore, daptomycin resistance. To test this hypothesis, we assessed the association 261 between rifaximin exposure and daptomycin-resistant VREfm in a retrospective patient cohort 262 at a quaternary referral healthcare centre in Melbourne, Australia. The *E. faecium* isolates 263 from patients with current or prior rifaximin exposure – "rifaximin" group – and without prior 264 exposure ("control" group) were assessed a) genomically for the RpoB amino acid substitutions (G482D, H486Y, and S491F) that result in daptomycin resistance and b) 265 266 phenotypically for daptomycin resistance, by study investigators blinded to patient details and 267 the exposure groups. The VREfm isolates were phylogenetically distributed and both rifaximin 268 and control group isolates were representative of the E. faecium strains identified in the statewide snapshot survey (Figure 3A)³². Isolates that were genomically clustered and likely to 269 270 represent patient-to-patient transmission were excluded from the analysis (see Methods). 271 Genetically distinct VREfm from 212 individual patients collected between 2014-2022 were 272 included in the analysis: 96 in the "rifaximin" exposed group and 116 in the unexposed 273 "control" group. Overall patient demographics of the cohort were balanced between the two 274 groups with the exceptions of age (P<0.001) and overall Charlson Comorbidity Index score 275 (P<0.001), which was driven by a significantly greater proportion of patients with chronic liver 276 disease in the rifaximin group (P<0.001) (Supplementary Table 2). As expected, there was also 277 significantly greater recent exposure to rifaximin (within the last 90 days prior to VREfm 278 sample collection) in the rifaximin group (P<0.001). Notably, only a single patient in the study 279 had received recent daptomycin.

280

Among the VREfm obtained from the entire (n=212) cohort, recent exposure to rifaximin was significantly associated with the presence of RpoB substitutions (*P*<0.001), including substitutions associated with daptomycin resistance (either G482D, H486Y, or S491F; *P*<0.001), and was significantly associated with carriage of daptomycin-resistant VREfm (*P*<0.001) (Figure 3B, Supplementary Table 3). More importantly, after adjusting for potential 286 confounders, recent rifaximin exposure remained an independent predictor of these 287 daptomycin resistance RpoB substitutions (OR 8.69; 95% CI 2.95-30.84; P<0.001) and 288 daptomycin-resistant VREfm (OR 6.47; 95% CI 2.34-20.80; P<0.001) among the overall cohort 289 of patients (Supplementary Table 4A-B). Given almost all patients who received rifaximin had 290 underlying chronic liver disease (with hepatic encephalopathy being the predominant 291 indication for rifaximin prescribing in Australia), we assessed the association between 292 rifaximin and daptomycin resistance first within the subgroup of patients with liver disease 293 (Supplementary Tables 5A-C), and then second, in an independent cohort of patients without 294 liver disease from the University Medical Center, Regensburg, Germany. These patients were 295 undergoing haematopoietic stem cell transplantation (HSCT), where rifaximin is used for 296 antimicrobial prophylaxis (Supplementary Tables 6A-C). The significant association between 297 rifaximin exposure and daptomycin resistance RpoB substitutions was again identified in both 298 patient groups – a) patients with chronic liver disease (P=0.001) and b) HSCT patients without 299 liver disease (P<0.001) (Supplementary Figure 10 and Supplementary Tables 5C and 6C). 300 Among the patients with liver disease colonised with VREfm, recent rifaximin was an 301 independent predictor of daptomycin-resistant VREfm (OR 4.37; 95% CI 1.70-12.84; P=0.004). 302 We conducted several other sensitivity analyses to verify the robustness of these associations 303 and assess for other confounders, including a subgroup analysis that excluded patients who 304 received rifaximin from the analysis (Supplementary Table 7), but these did not identify any 305 other associations between daptomycin resistance and underlying disease or antibiotic 306 exposure.

307

308 There were six patients from the "control" group with daptomycin-resistant VREfm – three 309 (50%) of these had isolates with no mutations in *rpoB*, suggesting an alternate mechanism for

resistance, while the remaining three patients had previously been admitted to the liver ward
for inpatient care, suggesting they may have acquired daptomycin-resistant VREfm through
healthcare-associated transmission.

313

While only one representative VREfm isolate from each patient was included in the above analysis, the *de novo* emergence of daptomycin-resistant VREfm carrying the G482D RpoB substitution was observed in one patient from whom multiple isolates were collected during rifaximin therapy, consistent with rifaximin exposure driving the *de novo* emergence of daptomycin-resistant VREfm.

319

Therefore, in agreement with our laboratory observations, these clinical data confirm a strong clinical association between recent rifaximin exposure and *rpoB* substitutions linked to daptomycin resistance among patients colonised with VREfm, suggesting exposure to rifaximin could drive daptomycin-resistant VREfm.

324

325 Rifaximin exposure leads to daptomycin-resistant VREfm in a murine model of 326 gastrointestinal colonisation.

We next used a mouse VREfm gastrointestinal colonisation model to understand if rifaximin exposure caused *de novo* emergence of *rpoB* mutations that confer cross-resistance to daptomycin. Mice were colonised with a daptomycin-susceptible (MIC 2 mg L⁻¹) clinical VREfm isolate (Aus0233) containing a WT *rpoB* allele before being administered a human-equivalent dose of either rifaximin, rifampicin, daptomycin, or vehicle (Figure 4A and Supplementary Figure 9). Rifampicin was chosen as a comparison since it is a rifamycin used in clinical practice. After 7 days of rifamycin treatment, we observed rifamycin-resistant VREfm in significantly more mice receiving rifampicin (80% of mice) or rifaximin (90% of mice) than in mice that received daptomycin (0% of mice) (P<0.0001 and P<0.0001; unpaired t-test) or vehicle (0% of mice) (P<0.0001 and P<0.0001; unpaired t-test) (Figure 4B).

337

338 For each mouse, we then determined the percentage of individual VREfm isolates that were 339 rifamycin-resistant or daptomycin-resistant. There were significantly more rifamycin-resistant VREfm isolated from mice receiving rifaximin or rifampicin than mice receiving the vehicle 340 341 control (P<0.0001 and P<0.0001; unpaired t-test) or daptomycin (P<0.001 and P<0.001; 342 unpaired *t*-test) (Figure 4D). Similarly, there was significantly more daptomycin-resistant 343 VREfm in mice receiving rifaximin or rifampicin than vehicle control (P<0.05 and P<0.05; unpaired t-test) or daptomycin (P<0.05 and P<0.05; unpaired t-test) (Figure 4E). We estimated 344 345 that daptomycin-resistant VREfm accounted for between 0-41% of the gastrointestinal VREfm 346 population in mice given rifaximin and 0-36% in mice given rifampicin, demonstrating 347 conclusively that rifamycin administration drives the emergence of VREfm with resistance to 348 rifamycins and cross-resistance to daptomycin. Notably, no daptomycin-resistant VREfm were isolated from mice receiving daptomycin, in agreement with prior research³⁵. 349

350

We then performed WGS on 150 randomly selected VREfm isolates from each group (rifaximin or rifampicin, n=300 total) to identify all mutations present in the rifamycin-resistant isolates. This collection consisted of 100 rifaximin or rifampicin-resistant isolates taken following the last day of treatment and 50 isolates from each group collected prior to rifamycin administration. No substitutions in RpoB were identified in any *E. faecium* isolate taken prior to rifaximin or rifampicin exposure. However, after exposure to either rifaximin or rifampicin, VREfm carrying mutations within *rpoB* were commonly identified. The S491F substitution was 358 most prevalent (n=53 [rifaximin] and n=63 [rifampicin]), with all isolates carrying this 359 substitution being daptomycin-resistant (Figure 4F). The H486Y substitution was identified at 360 a reduced frequency compared to the S491F, (n=12 [rifaximin] and n=28 [rifampicin], 361 respectively), with all isolates again being daptomycin-resistant. The G482D substitution was 362 the third most commonly identified RpoB substitution (n=15 [rifaximin] and n=6 [rifampicin], 363 respectively), with 19 isolates carrying this substitution being daptomycin-resistant. Other RpoB substitutions in addition to S491F, H486Y, and G482D were also identified. These 364 365 substitutions included V135F, L471V, Q473L, and H486R, however all VREfm isolates carrying 366 these substitutions were daptomycin-susceptible. Importantly, the proportions of each RpoB 367 substitution observed in VREfm collected from the gastrointestinal tract of mice administered 368 either rifaximin or rifampicin, closely matched the proportions of each mutation observed in 369 our collection of human clinical VREfm isolates, with the S491F substitution most commonly 370 identified, followed by H486Y, and then G482D. These observations in our mouse model 371 strongly suggest that exposure to rifaximin is driving the *de novo* emergence of daptomycin 372 resistance in colonising strains of *E. faecium* in humans.

373

374 VREfm with daptomycin-resistant RpoB substitutions have changes in the cell membrane
 375 lipid profile and increased expression of the *prdRAB* regulon.

To understand how amino acid substitutions in the ß subunit of the bacterial RNA polymerase (RpoB) cause resistance to daptomycin, a cell membrane active antibiotic, we utilised a multiomics approach. We started by analysing the lipidomes of the three isogenic daptomycinresistant RpoB mutants (G482D, H486Y, or S491F) compared to WT VREfm. We additionally included an isogenic RpoB mutant that did not confer resistance to daptomycin (Q473L; daptomycin MIC 2 mg L⁻¹) created from the same WT VREfm isolate as a comparison. Principal382 component analysis (PCA) of the detected lipids clearly separated the daptomycin-resistant 383 RpoB mutants from the WT and daptomycin-susceptible Q473L strain, indicating distinct lipid 384 profiles (Figure 5A). While the same classes of lipid species were observed in the WT and 385 daptomycin-resistant RpoB mutants, there were significant reductions in anionic cardiolipins 386 (CL) and phosphatidylglycerols (PG), as well as an increase in digalactosyldiacylglycerols 387 (DGDG) and cationic lysyl-PGs (Lys-PG) in the RpoB mutants (Figure 5B-E). CL, PG, DGDG, and Lys-PG profiles returned to WT when each of the three RpoB mutations was reverted, 388 389 demonstrating that the differences observed in the daptomycin-resistant strains were due to 390 the RpoB substitutions (Supplementary Table 8).

391

392 Given the central role of RpoB in transcription, we hypothesised the lipidome differences of 393 the daptomycin-resistant RpoB mutants were caused by alterations in gene expression. We 394 firstly modelled the RNA polymerase complex structure in *E. faecium* to estimate the changes 395 imparted by Q473L, G482D, H486Y, and S491F substitutions on transcription at the protein 396 level. All four substitutions were present at the rifamycin active site and in direct interaction 397 with nucleic acids at the transcription replication fork, with predicted changes in stability or 398 altered interactions with nucleic acid templates (Supplementary Figure 10). The highly 399 prevalent S491F substitution defined changes to a bulkier hydrophobic side chain, with 400 predicted mild reductions in protomer stability and affinities to rifampicin, other RNA polymerase subunits, and nucleic acids within the replication fork. Thereby suggesting that 401 402 even at objectively low reductions in affinity, this mutation can directly impact the 403 transcription rate, and the subsequent rate of gene expression. Conversely, the G482D 404 substitution resulted in the introduction of a bulkier negatively charged side chain, which led 405 to steric clashes and increased electrostatic potential of the RNA binding cleft. The G482D

406 substitution was predicted to have the largest detrimental effect on protein stability, which 407 may reduce the amount of active RNA polymerase and gene expression. Interestingly, it was 408 also predicted to increase nucleic acid binding affinity of the mutant complex, further reducing 409 RNA polymerase activity and processing. Finally, the daptomycin-resistant substitution H486Y 410 and daptomycin-susceptible substitution Q473L were predicted to confer similar effects to the 411 protein stability, and rifampicin and nucleic acid binding affinity. However, the H486Y 412 substitution, but not the Q473 substitution, was predicted to increase RNA polymerase 413 complex stability, reducing the dynamic flexibility required for enzyme activity, potentially 414 leading to the changes in gene expression. Overall, the daptomycin-resistant substitutions 415 S491F, H486Y, and G482D were all characterised by distinct interactions from the WT RNA 416 polymerase while the daptomycin-susceptible substitution Q473L retained the original WT 417 interactions.

418

419 Given the predicted changes in RNA polymerase transcriptional activity, we used a 420 combination of RNA sequencing (RNAseq) and data independent acquisition (DIA) based 421 proteomics and identified 26 loci that were significantly differentially expressed in both 422 RNAseq and proteomics in all three daptomycin-resistant strains (G482D, H486Y, and S491F), 423 but not in the daptomycin-susceptible strain (Q473L) or the WT VREfm (Figure 5F and 424 Supplementary Table 9). Of note, there was no differences in expression (by transcriptomics or proteomics) of the *liaFSR*, *liaXYZ*, or *yycFG* (*walKR*) regulons or the cardiolipin synthase (*cls*) 425 426 or division site tropomyosin (divIVA) genes, indicating the mechanism of RpoB-mediated daptomycin resistance was independent of previously described systems^{10,11,21}. Since 427 428 compensatory rpoC mutations can alter the kinetic parameters of the RNA polymerase 429 enzyme, we hypothesised the number of dysregulated genes would decrease in the RpoBC 430 double mutant (RpoB S491F and RpoC T634K) compared to the single RpoB S491F mutant, 431 leaving genes likely associated with daptomycin resistance. Indeed, only six loci were 432 differentially expressed (by RNAseq and proteomics) in the RpoBC mutant, compared with 44 433 loci identified in the single RpoB S491F mutant (Figure 5F-G). These included genes encoding 434 a cold shock protein (CspA, [protein] AGS75480 or EFAU233 01583), a hypothetical protein of 435 unknown function, a potassium uptake transporter (K+ transporter, [protein] AGS74117 or 436 EFAU233 00176), and a DNA-binding transcriptional regulator of the PadR family in a putative 437 operon with two hypothetical membrane proteins ([proteins] AGS74325, AGS74326, 438 AGS74327 or EFAU233 00444, EFAU233 00445, EFAU233 00446). All six of these loci were 439 significantly upregulated (in RNAseq and proteomics) in the three daptomycin-resistant RpoB 440 mutants (G482D, H486Y, and S491F), as well as in the RpoBC double mutant.

441

442 To understand their potential role in daptomycin resistance, each of these six genes were 443 deleted from the WT and RpoB S491F mutant. The *dltC* gene, linked to daptomycin resistance 444 in S. aureus, was also included as it was differentially expressed in the G482D, H486Y, and S491F strains, but not in the RpoBC double mutant. Deletion of *cspA*, *dltC*, the hypothetical 445 446 protein, or K+ uptake transporter did not alter daptomycin susceptibility in either the WT or 447 RpoB S491F backgrounds. However, deletion of the PadR-family regulator (named here prdR, 448 Phenotypic Resistance to Daptomycin Regulator) or individual deletions of the hypothetical membrane proteins (named here prdA and prdB) increased daptomycin susceptibility by 4-449 450 fold in the WT or S491F backgrounds (Figure 5H; Supplementary Figure 11A). Similar 4-fold 451 increases in daptomycin susceptibility were observed when these genes were deleted from 452 the RpoB G482D or H486Y backgrounds (Figure 5H).

454 Clinical paired VREfm isolates representative of the G482D, H486Y, and S491F mutations were 455 analysed by DIA proteomics to examine the abundance of PrdR, PrdA, and PrdB in the cell. In 456 daptomycin-resistant clinical strains carrying the S491F (ST1421 and ST203), G482D (ST80), or 457 H486Y (ST203) mutations, the production of PrdRAB was significantly (P<0.05) increased 458 compared to daptomycin-susceptible (WT rpoB allele) strains of the same ST (Supplementary 459 Figure 11B-C and Supplementary Table 9). The increased expression of PrdRAB in both 460 genetically distinct clinical VREfm harbouring the G482D, H486Y, or S491F mutations and in 461 isogenic strains, suggested the *prdRAB* operon was responsible for RpoB-mediated 462 daptomycin resistance.

463

464 Upregulation of the *prdRAB* operon leads to cell membrane remodelling and decreased 465 daptomycin binding in daptomycin-resistant RpoB strains.

466 We hypothesised the overexpression of the prdRAB operon in the RpoB mutants was leading 467 to the observed changes in the cell membrane and subsequent resistance to daptomycin. 468 Therefore, an overexpression vector with the *prdR* gene, along with an empty vector (EV) 469 control, were introduced separately into the WT VREfm. Consistent with this, plasmid mediated overexpression of the *prdR* gene increased the WT daptomycin MIC 4-fold, to 8 mg 470 L⁻¹. Proteomic analysis (WT EV versus WT^{prdR}) confirmed the *prdR* regulator was expressed to 471 472 a similar level in the WT^{prdR} strain as in the RpoB mutants (2.5-fold and 2.2-fold in S491F, 473 respectively) and the prdR regulator specifically controlled the expression of the prdAB 474 membrane proteins (Supplementary Figure 12A and Supplementary Table 9). PCA of the WT, WT EV, WT^{prdR}, and RpoB S491F lipidomes supported the overexpression of the prdR gene 475 driving the changes in the lipid species, with the WT^{prdR} and RpoB S491F lipidomes clustering 476 477 separately than the WT and WT EV lipidomes (Figure 6A and Supplementary Table 8).

478 Reductions in the same anionic phospholipids (CL and PG) and increases in cationic Lys-PG species were observed in the WT^{prdR} strain to similar levels seen in the RpoB S491F mutant 479 480 (Figure 6B-C and Supplementary Figure 12B). Lipidomic analyses of the previously described 481 paired clinical isolates demonstrated the daptomycin-resistant clinical strains carrying RpoB 482 mutations had similar significant differences in charged phospholipids (decreases in CL and 483 PG, increases in Lys-PG), compared to daptomycin-susceptible strains containing the WT rpoB 484 allele (Figure 6D and Supplementary Table 8). These data indicated that overexpression of the 485 prdRAB operon in daptomycin-resistant VREfm carrying RpoB mutations leads to changes in 486 the abundance of charged lipid species in the cell membrane.

487

488 Given the decreases in anionic phospholipids (CL and PG) and increases in cationic 489 phospholipids (Lys-PG), we tested if strains harbouring RpoB mutations harbour differences in 490 overall cell membrane charge and daptomycin binding. As we predicted, both the daptomycin-491 resistant isogenic and clinical RpoB mutants (G482D, H486Y, and S491F) had a significantly 492 reduced negative charge associated with the cell membrane compared to their paired isolate 493 (Figure 6E and Supplementary Figure 13A), respectively, and consequently bound less 494 fluorescent daptomycin (Figure 6F and Supplementary Figure 13C). Complementation of the 495 RpoB mutations reversed cell membrane charge and daptomycin binding to WT levels 496 (Supplementary Figure 13B and D). No significant difference was observed in membrane 497 charge or daptomycin binding for the daptomycin-susceptible Q473L strain (Figure 6E-F). 498 Further, the overexpression of the *prdR* gene resulted in a significantly reduced negative 499 charge across the cell membrane compared to the WT EV strain, with a similar charge to the 500 daptomycin-resistant RpoB mutants (Figure 6F). Additionally, binding of daptomycin was 501 significantly decreased compared to the WT EV strain (Figure 6F). These experiments show

that the increased expression of the *prdRAB* operon in VREfm carrying daptomycin resistance
associated RpoB mutations leads to changes in the abundance of charged phospholipids and
a decrease in the cell surface negative charge, which in turn reduces daptomycin binding to
the cell membrane.

506

507 Discussion

508 Here we show that specific amino acid substitutions within the RRDR of RpoB (G482D, H486Y, 509 and S491F) lead to clinical daptomycin resistance in *E. faecium*. These mutations are globally 510 distributed with prevalence equal to other well-characterised amino acid substitutions within 511 LiaFSR/LiaXYZ and Cls, which have been considered the dominant mechanisms of daptomycin resistance in VREfm^{21,38,39}. Although these findings are reminiscent of previous studies in S. 512 513 aureus, which have suggested that rpoB mutations can lead to reduced daptomycin 514 susceptibility, there are some important distinctions^{40–42}. In *S. aureus, rpoB* mutations have 515 not been reported to result in clinical daptomycin resistance (defined as MIC \geq 2 mg L⁻¹), as 516 seen here in VREfm - rather they are associated with subtle changes in daptomycin 517 susceptibility. There are no reports in the literature of *rpoB* mutations leading to daptomycin 518 resistance in clinical S. aureus isolates, suggesting that rpoB mutations may be of limited 519 clinical importance to S. aureus daptomycin resistance. This contrasts with VREfm, where rpoB 520 mutations appear to be a major mechanism of daptomycin resistance. Through our multi-omic approach we have defined the molecular mechanism by which rpoB mutations lead to 521 522 changes in daptomycin susceptibility in VREfm. Our analyses show that G482D, H486Y, and 523 S491F RpoB substitutions mediate daptomycin resistance via a conserved mechanism that is 524 independent of previously described systems (Lia operons or Cls). Each of these RpoB 525 substitutions caused similar transcriptional reprograming in VREfm, with dysregulation of a

526 previously uncharacterised genetic locus found to be responsible for daptomycin resistance. 527 The locus, that we have named the Phenotypic Resistance to Daptomycin (prd) operon 528 consists of a transcriptional regulator (PrdR) and two putative membrane proteins (PrdAB). 529 Upregulation of the *prdRAB* operon leads to cell membrane remodelling, with decreased 530 levels of anionic phospholipids (PG and CL) and increased levels of cationic phospholipids (Lys-531 PG). This ultimately decreases the negative cell surface charge and reduces daptomycin 532 binding, which renders VREfm resistant to daptomycin. Notably, there was no dysregulation 533 of the *prdRAB* operon in an isogenic VREfm strain carrying an RpoB substitution (Q473L) that 534 did not confer daptomycin resistance and no membrane changes relative to the daptomycin-535 susceptible WT were observed. The G482D, H486Y, and S491F RpoB substitutions studied here 536 should therefore be considered clinically relevant and major mediators of daptomycin 537 resistance in VREfm.

538

The S491F RpoB substitution in particular is common within the global *E. faecium* population, being present in at least three phylogenetically distinct lineages currently circulating within healthcare systems in Australia, the United Kingdom, the United States, and across Europe. These lineages have spread over global geographic scales and persisted for at least 15 years, which is of clinical concern since it suggests that they might eventually compromise the therapeutic value of daptomycin for treating VREfm infections.

545

546 Exposure to rifamycin antimicrobials is a well-documented driver in the emergence of 547 bacterial strains carrying substitutions in RpoB, with mutations in this gene often leading to 548 high level rifamycin resistance²⁴. In keeping with this, VREfm isolates carrying the G482D, 549 H486Y, and S491F RpoB substitutions are resistant to rifamycin antimicrobials in addition to 550 daptomycin, suggesting that rifamycin use might be an important driver in the emergence of 551 daptomycin-resistant VREfm. In support of this, our data suggests the clinical use of rifaximin 552 is likely responsible for driving VREfm isolates harbouring mutations within rpoB that are 553 cross-resistant to rifamycins and daptomycin. Three lines of evidence support this hypothesis: 554 (i) Bayesian phylodynamic analyses show the emergence of phylogenetically distinct VREfm 555 lineages carrying the S491F substitution is temporally linked with the clinical approval of 556 rifaximin in the early 2000s, with each lineage subsequently undergoing population expansion 557 following FDA approval in 2010 of rifaximin as a prophylactic for the prevention of hepatic 558 encephalopathy in chronic liver disease patients, (ii) two independent retrospective patient 559 cohort studies demonstrate that recent rifaximin exposure was predictive of carriage of 560 daptomycin-resistance RpoB substitutions, and (iii) animal experiments demonstrate the 561 administration of rifaximin to mice colonised with VREfm led to the *de novo* emergence of 562 VREfm strains within the gastrointestinal tract that carried substitutions within RRDR of RpoB 563 and were resistant to rifamycins and cross-resistant to daptomycin.

564

565 Although both rifaximin and rifampicin could drive the *de novo* emergence of daptomycin-566 resistant VREfm in the mice experiments of our study, the data overall do not support a 567 prominent role for rifampicin in the emergence of daptomycin-resistant VREfm. This 568 hypothesis is based on a lack of temporal signal between the emergence of daptomycin-569 resistant VREfm carrying RpoB substitutions (circa 2006) and the clinical introduction of 570 rifampicin which occurred in the early 1970s, as well as the observation that the vast majority 571 of daptomycin-resistant VREfm were only isolated from patients who received rifaximin in our 572 clinical analyses (and not from the control group). Why rifaximin appears to be a driver of 573 daptomycin resistance in *E. faecium* while rifampicin does not, is not immediately clear, but 574 may relate to the patient cohorts that rifampicin and rifaximin are primarily used to treat. 575 Rifaximin is used in patients with chronic liver disease who are recognised as one of the 576 highest risk groups for gastrointestinal VREfm carriage, while rifampicin and other rifamycins 577 are used in broader cohorts that are not frequently colonised with *E. faecium*. Our hypothesis 578 is that patients with chronic liver disease receiving rifaximin are a major source for the 579 emergence and subsequent spread of daptomycin-resistant VREfm carrying rpoB mutations. 580 Our analysis of the HSCT patient cohort demonstrates that this phenomenon is not restricted 581 to liver disease patients and is more generalisable, such that any patient colonised with VREfm 582 and receiving rifaximin is at risk of *E. faecium* carrying *rpoB* mutations that are daptomycin-583 resistant emerging within the gut. There are some important clinical implications from this. 584 First, our results suggest that daptomycin should not be used for empiric therapy of invasive 585 VREfm infections in patients who are receiving rifaximin, or have recently received rifaximin, 586 given the significantly higher risk of daptomycin resistance. Secondly, to preserve the use of 587 daptomycin for VREfm, consideration should be given to maintaining isolation precautions in 588 hospitals for patients receiving rifaximin who are colonised with VREfm, avoiding cohorting 589 with other VREfm colonised patients where possible. Thirdly, although effective for 590 prophylaxis against hepatic encephalopathy, consideration should be given to keeping 591 rifaximin as a second-line option behind other therapies for this indication, and the use of 592 rifaximin for prophylaxis following HSCT reconsidered, given the propensity to induce 593 mutations in *rpoB* and subsequent daptomycin resistance.

594

595 There is a coordinated global effort to preserve the use of last-resort antimicrobials through 596 strict stewardship protocols that try to limit the use of these critically important medicines. 597 The rationale for this strategy assumes that restricted antibiotic usage equals less opportunity for pathogens to develop resistance. Here we show that this assumption may be flawed, since exposure to prophylactic rifaximin can lead to the emergence of daptomycin-resistant VREfm in the absence of daptomycin exposure. These data highlight that unanticipated antimicrobial cross-resistance can readily arise following the implementation of new antimicrobial regimes, even when they are perceived to be "low-risk". Careful consideration should therefore be given to the potential impact of prophylactic antibiotics on antimicrobial stewardship practices.

605

We have identified a previously unrecognised, globally important mechanism of last-resort antibiotic resistance in VREfm and show that prophylactic rifaximin use, particularly in chronic liver disease patients, is a cause of this resistance. These findings demonstrate the ease with which new antibiotic treatment regimens can drive the emergence of multidrug-resistant pathogens and highlight the impact that unanticipated antibiotic cross-resistance can have on antibiotic stewardship efforts designed to preserve the use of last-resort antibiotics. We advocate for the judicious use of all antibiotics.

614 Methods

615 Media and reagents

- 616 *E. faecium* was routinely cultured at 37°C in brain heart infusion (BHI) broth (Becton Dickson)
- or BHI agar (BHIA), BHI solidified with 1.5% agar (Becton Dickson). For electroporation, E.
- 618 faecium was cultured in BHI supplemented with 3% glycine and 200 mM sucrose (pH 7.0). E.
- 619 coli was cultured in Luria broth (LB). Broth microdilution (BMD) MICs were performed in
- 620 cation-adjusted Mueller Hinton with TES broth (CAMHBT) (Thermo Fisher). A concentration of
- 621 10 mg L⁻¹ chloramphenicol (Sigma Aldrich) was used for plasmid selection in *E. faecium* and *E.*
- *coli*. The following antibiotics were used at variable concentrations for susceptibility testing:
- 623 rifampicin (Sigma Aldrich), rifaximin (Sigma Aldrich), and daptomycin (Cubicin).
- Oligonucleotides were purchased from Integrated DNA Technologies and are listed in
 Supplementary Table 11. Plasmids were purified with Monarch Plasmid Miniprep Kit (NEB).
 PCR products and gel extractions were purified using Monarch DNA Gel Extraction Kit (NEB).
- 627 Genomic DNA was purified using the Monarch Genomic DNA Purification Kit (NEB). Phusion
- 628 and Phire DNA polymerase was purchased from NEB.

629 Bacterial isolates

630 Bacterial strains used in this study are listed in Supplementary Table 10. Australian bacterial 631 strains were collected across three data projects in the Microbiological Diagnostic Unit Public 632 Health Laboratory (MDU PHL). Two unbiased cross-sectional surveys of VREfm were conducted between 10 November and 9 December 2015 (n=331)³² and between 1 November 633 634 and 30 November 2018 (n=323) in the State of Victoria (referred to as the 2015 and 2018 635 Snapshot). During this period, all VREfm-positive isolates (including screening and clinical 636 samples) collected by laboratories across the state were sent to the MDU PHL. In addition, 637 this project included vanA-VREfm collected from the "Controlling Superbugs" study^{19,20}, a 15month (April-June 2017 and October 2017-2018) prospective study including eight hospital
sites across four hospital networks, resulting in 346 VREfm isolates (308 patients) sent for WGS
at MDU PHL. The VREfm were isolated from patient samples (including screening and clinical
samples) routinely collected from hospital inpatients. For the 'historical *vanA*-VREfm,' every *vanA* isolate collected within MDU PHL was included. This resulted in an additional 229
isolates, sampled between 2003 and 2014.

For publicly available isolates, our aim was to capture the diversity of *E. faecium* circulating 644 645 globally by including isolates that formed part of several key studies involving hospital-646 associated VREfm (as of January 2021). To be included, isolates needed to have short-read 647 data available, with geographic location (by country), year of collection, and source (human 648 or animal). Reads were only included if they had a sequencing depth of >50x. To capture the 649 diversity of VREfm circulating in the United States, isolates from human sources were 650 downloaded from the PathoSystems Resource Integration Center⁴³. All isolates were confirmed to be *E. faecium* with the Kraken2 database (v.2.1.2)⁴⁴. The final number of 651 652 international isolates comprised those from Africa (n=8), Asia (n=25), Europe (n=2941), North America (n=424), and South America (n=78) (Supplementary Table 10). 653

654 Antibiotic susceptibility testing

Daptomycin susceptibility testing was performed using the BMD MIC method according to CLSI guidelines. In a 96-well plate, a two-fold dilution series (from 32 to 0.5 mg L⁻¹) of daptomycin was made in 100 μ L volumes of CAMHBT, additionally supplemented with 50 mg L⁻¹ Ca²⁺. An inoculum of 100 μ L *E. faecium* broth culture adjusted to 1 x 10⁶ CFU mL⁻¹ in CAMHBT was then added to each well. After 24 hours incubation, the MIC was defined as the lowest antimicrobial concentration that inhibited visible growth. All assays were performed in biological triplicate, with the median MIC reported. In accordance with recent guidelines⁴⁵, isolates with a daptomycin MIC \ge 8 mg L⁻¹ were considered to be daptomycin-resistant. A daptomycin-sensitive strain (AUS0085)⁴⁶ and a daptomycin-resistant strain (DMG1700661)¹⁶ were used as a control.

Rifampicin susceptibility testing was performed using the BMD method in CAMHBT. High-level rifampicin resistance was defined with a MIC > 32 mg L⁻¹. All susceptibility testing was performed in triplicate.

668 Whole-genome sequencing

Genomic DNA was extracted from a single colony using a JANUS automated workstation 669 670 (PerkinElmer) and Chemagic magnetic bead technology (PerkinElmer). Genomic DNA libraries 671 were prepared using the Nextera XT kit according to manufacturer's instructions (Illumina, 672 San Diego, CA, USA). Whole-genome sequencing was performed using Illumina NextSeq 673 platform, generating 150 bp paired-end reads. The short reads of isolates sequenced at MDU-674 PHL are available on the NCBI Sequence Read Archive [BioProjects PRJNA565795 (Controlling 675 Superbugs), PRJNA433676 (2015 Snapshot) and PRJNA856406 (2018 Snapshot), and 676 PRJNA856406 (historical vanA isolates)].

677 Phylogenetic analysis

De novo assemblies of the genomes were constructed using Spades⁴⁷ (v3.13). In silico MLST 678 database⁴⁸ 679 determined using the program mlst with the efaecium was 680 (https://github.com/tseemann/mlst). The 1000 Australian genomes as well as the 4,705 681 Australian and international VREfm were mapped to the reference E. faecium genome 682 AUS0085 isolated from a human bacteraemia infection in Victoria, Australia (NCBI accession: CP006620)⁴⁶ using snippy (https://github.com/tseemann/snippy) (v4.4.5), applying a minfrac 683 value of 10 and mincov value of 0.9. This reference was selected as it was a publicly available 684 685 complete genome collected locally and daptomycin-susceptible. A maximum likelihood

phylogenetic tree was inferred using IQ-TREE (v2.1.2)⁴⁹ with a general time-reversible (GTR + G4) substitution model, including invariable sites as a constant pattern and 1000 bootstrap replicates. Recombination masking was not performed for species maximum likelihood trees due to the small size of the resulting core alignment. All trees were mid-point rooted and visualised in R (v4.0.3, https://www.r-project.org/) using phangorn⁵⁰ (v2.5.5), ape⁵¹ (v5.4),

- 691 ggtree⁵² (v2.3.4), and ggplot (v3.3.2).
- The genome assemblies of all isolates were screened for acquired antimicrobial resistance
- 693 determinants using abriTAMR (https://github.com/MDU-PHL/abritamr)⁵³.

694 Genome-wide association study of daptomycin resistance

A GWAS approach was applied to identify genetic variants of daptomycin resistance in E. 695 faecium. A genotype matrix of SNPs was constructed and used as input to homoplasyFinder⁵⁴ 696 697 (v0.0.0.9) to determine the consistency index at each locus and kept mutations that had an 698 index of ≤0.5 (indicating at least two independent acquisitions across the phylogeny). We then 699 ran GWAS using daptomycin resistance as a binary trait, where isolates were categorised as 700 resistant if their daptomycin MIC was $\geq 8 \text{ mg L}^{-1}$. To correct for population structure, we used 701 the factored spectrally transformed linear mixed models (FaST-LMM) implemented in pyseer⁵⁵ 702 (v.1.3.6), which computes a kinship matrix based on the core genome SNPs as a random effect. 703 P values were corrected for multiple hypothesis testing using the Bonferroni correction 704 method.

705 Competition assay

For competition assays, overnight cultures of WT and corresponding RpoB S491F or RpoB
S491F/RpoC T634K mutants were diluted to an OD600 of 0.5 in BHI and equal volumes added
to an overnight culture. Serial dilutions of each co-culture were performed at times 0 and 24

hours on BHIA. Colonies were then replica plated onto BHIA and BHIA rifampicin 20 μg mL⁻¹

710 to determine the proportion of WT to mutant.

711 Core genome MLST (cgMLST) and clustering

cgMLST alleles for each isolate was defined using the public *E. faecium* cgMLST scheme⁵⁶ and 712 chewBBACA (v2.0.16)⁵⁷, implemented locally in the COREugate pipeline (v2.0.4) 713 714 (https://github.com/kristyhoran/Coreugate). The pipeline determines the alleles of each core 715 gene for every isolate as defined by the specific pathogen scheme. The *E. faecium* cgMLST 716 scheme contains 1,423 genes. The number of allelic differences between each isolate within 717 this core set of genes is then determined. The cgMLST clusters were determined using single linkage clustering and a pairwise allelic difference threshold of ≤250. This threshold was 718 719 chosen since it maximised diversity within clusters, to improve temporal sampling depth, 720 while still clustering based on maximum-likelihood tree structure.

721 Phylodynamic analyses of the emergence of the S491F RpoB mutation in VREfm lineages

722 To investigate the emergence of the S491F mutation in RpoB in three different lineages, as 723 defined with cgMLST, we undertook further analysis on these clusters/lineages. From the 724 species-level maximum-likelihood tree (Figure 2C), three lineages/clusters were identifiable 725 by cgMLST due to their size (n>50) and presence of the S491F mutation. The three clusters 726 were analysed independently, such that individual core-genome SNP alignments were 727 generated, since this increased the length of the core alignment and number of sites 728 considered. Snippy (https://github.com/tseemann/snippy) (v4.4.5) was used to generate the 729 alignments cluster corresponding for each to the reference genome (AUSMDU00004024/CP027517.1 for Cluster 1, AUSMDU00004055/CP027506.1 for Cluster 2, 730 731 and AUSMDU00004142/CP027501.1 for Cluster 3). Each core alignment used a within 'cluster 732 reference' (complete genome of the same cluster) to maximise core-SNP alignment length.

733 The reference for each cluster was chosen since they were a locally-collected, closed genome. 734 Recombination was removed from the final alignment using Gubbins⁵⁸ (v.2.4.1) to ensure 735 modelling was only informed by SNPs with tree-like evolution within the core genome. 736 Maximum-likelihood trees for each of the three clusters were inferred from the core-SNP 737 alignments [Cluster 1: (n=219 taxa) 329 SNPs; Cluster 2: (n=85 taxa) 541 SNPs; Cluster 3: (n=68 738 taxa) 764 SNPs] with IQ-tree (v2.1.2)⁵⁹ with a general time-reversible (GTR+G4) substitution 739 model, including invariable sites as a constant pattern. Phylogenetic uncertainty was 740 determined through 1000 nonparametric bootstrap replicates.

To investigate temporal signal in the three clusters of VREfm genomes, we first used TempEst⁶⁰ (v1.5). A root-to-tip regression analysis was performed on the root-to-tip branch distances within the three, cluster maximum-likelihood phylogenies as a function of year of collection, with the position of the root optimised according to the heuristic residual mean squared method.

746 The frequency of the emergence of the *rpoB* mutation in VREfm was inferred using a discrete trait model implemented in BEAST⁶¹ (v1.10.4). Under this model the SNP alignments are used 747 748 to infer the evolutionary process (i.e. phylogenetic tree, time, and nucleotide substitution 749 model parameters) for the three clusters. The alignments all shared the HKY substitution 750 model and a constant-size coalescent population prior²⁶. To avoid ascertainment bias due to 751 using a SNP alignment, the number of constant sites were considered for the likelihood calculations. The molecular clock was a relaxed clock with an underlying lognormal 752 753 distribution. The molecular clock was calibrated using isolation dates for each genome by year 754 of collection and the mean clock rate is shared between all three alignments, but the model 755 allows for the individual alignments to have different standard deviations of the lognormal 756 distribution and also different branch rates. The mean molecular clock rate requires an explicit prior distribution, for which we used a Gamma distribution and a 0.95 quantile range of 4.9x10⁻⁶ and $1.1x10^{-4}$ substitutions/site/year. This informative prior means that it acts as an additional source of molecular clock calibration.

The presence or absence of the S491F mutation in *rpoB* was used as a binary trait^{62,63}. The 760 761 trait model was shared between the three alignments, with the different Markov jumps and 762 rewards (i.e. changes of trait state and time spent in each state, respectively) recorded for 763 each of the three alignments. The posterior distribution of model parameters was sampled 764 using a Markov chain Monte Carlo of 100,000,000 iterations, sampling every 100,000 765 iterations. Two independent runs were run for the models. We assessed sufficient sampling 766 from the stationary distributions by verifying the effective sample size of key parameters was 767 around or above 200. The final maximum-clade credibility trees were visualised in R (v4.0.3, 768 https://www.r-project.org/) using ggtree⁵² (v2.3.4). The Markov jumps for the *rpoB* trait for 769 each alignment were visualised in R (v4.0.3, https://www.r-project.org/).

770 Construction of isogenic mutants using allelic exchange and of pRAB11^{prdR}

The *rpoC*^{T634K}, *rpoB*^{G482D}, *rpoB*^{H486Y}, *rpoB*^{S491F}, *rpoB*^{Q473L}, ABC transporter (I274S), permease 771 772 protein (G71S), or mannitol dehydrogenase (V288L) mutations were recombined into the chromosomal copy of each gene in ST796 VREfm (Ef aus0233) by allelic exchange. Deletions 773 774 of the CpsA, K+ transporter, hypothetical protein, DltC, or PrdRAB were also completed using 775 allelic exchange. The region encompassing each gene was amplified by SOE-PCR and recombined into pIMAY-Z⁶⁴ by the seamless ligation cloning extract (SLiCE)⁶⁵ method and 776 transformed into *E. coli* IM08B⁶⁴. The construct was transformed into electrocompetent 777 VREfm⁶⁵, with allelic exchange performed as described previously⁶⁶. Reversion of *rpoB*^{G482D}, 778 *rpoB*^{H486Y}, or *rpoB*^{S491F} mutations were completed using allelic exchange with a construct 779 780 containing the respective wild-type allele. To construct a vector containing prdR, the vector pRAB11 was used. The *prdR* gene was amplified using Aus0233 genomic DNA. The *prdR*product was gel extracted, SLiCE cloned into amplified pRAB11, and transformed into IMO8B,
yielding pRAB11:*prdR*. The plasmid and empty vector was then electroporated into Aus0233.
Genome sequencing and analysis of all mutants was conducted as described, with resulting
reads mapped to the Ef_aus0233 reference genome and mutations identified using Snippy
(https://github.com/tseemann/snippy) (v4.4.5).

787 VREfm in vivo gastrointestinal colonisation experiments

Female C57BL/6 mice at 6-8 weeks of age were purchased from WEHI and maintained in a specific-pathogen-free facility at the Peter Doherty Institute for Infection and Immunity. All animal handling and procedures were performed in a biosafety class 2 cabinet. Animal procedures were performed in compliance with the University of Melbourne guidelines and approved by the University's Animal Ethics Committee.

793 The dose for each antibiotic was calculated using the FDA human conversion formula to ensure each mouse was given a human-equivalent dose⁶⁷. To establish gastrointestinal 794 795 colonisation of VREfm, mice were administered ceftriaxone (410 mg kg⁻¹ day⁻¹; AFT 796 Pharmaceuticals) via subcutaneous injection once daily for 4 days, followed by an antibiotic wean period of 24 hours. Mice were then inoculated with 10^6 VREfm in 100 μ l PBS by oral 797 798 gavage. Three days after VREfm inoculation, single-housed mice were administered either rifaximin (113 mg kg⁻¹ administered twice daily; Sigma Aldrich), rifampicin (123 mg kg⁻¹ 799 800 administered once day; Sigma Aldrich), or vehicle (Corn oil with 10% DMSO) via oral gavage; or daptomycin (50 mg kg⁻¹ administered once daily; Cubicin) via subcutaneous injection [this 801 results in similar exposure (AUC₀₋₂₄) to that observed in humans receiving 8 mg kg⁻¹ of 802 803 intravenous daptomycin⁶⁸]. The above antibiotic dosing protocol was followed for 7 days. 804 Faecal samples were collected at specific time points throughout the experiment to determine

VREfm gut colonisation and for downstream rifamycin and daptomycin resistance analysis.
Faecal samples were resuspended in PBS to a normalised concentration (100 mg ml⁻¹). Serial
dilutions were performed, and samples were plated onto Brilliance VRE agar (Thermo Fisher)
for VREfm CFU enumeration.

For rifamycin and daptomycin analysis, VREfm colonies (n=50 per mouse) from the Brilliance VRE agar plates were replica plated onto BHIA with and without rifampicin 20 μg mL⁻¹ to determine the proportion of rifampicin-resistant VREfm in each mouse. Fifty colonies per mouse were then screened for daptomycin resistance, with a single colony being resuspended in PBS, then diluted 1/100 into CAMHBT containing 50 mg L⁻¹ Ca²⁺, and 1/100 in CAMHBT containing 50 mg L⁻¹ Ca²⁺ and 8 mg L⁻¹ daptomycin. All suspected daptomycin-resistant colonies were confirmed using a daptomycin BMD MIC as before.

To determine which mutations were present in the rifamycin-resistant isolates, a random selection of 300 colonies, 150 from rifaximin treated mice and 150 from rifampicin treated mice (50 pre and 100 post for each treatment), were sampled for WGS as described above.

819 Analysis of patients receiving rifaximin for hepatic encephalopathy prophylaxis.

820 To examine the potential association between rifaximin exposure and daptomycin-resistant 821 VREfm, we analysed VREfm collected between 2014 and 2022 from a single quaternary 822 hospital institution in Melbourne. 225 patients were assessed for previous exposure to 823 rifaximin, which was defined as at least a single dose administered prior to the collection date for the VREfm isolate, and grouped into "Rifaximin-exposed" and unexposed "Control" groups. 824 825 Only a single isolate was selected at random for testing and analysis from patients who had 826 multiple samples with VREfm isolates. The VREfm isolates underwent WGS and daptomycin 827 and rifampicin susceptibility testing as before. Patients with VREfm isolates that were assessed 828 as genetically clustered with other VREfm isolates in the cohort and likely represented direct

829 transmission were excluded. Genetic clustering was defined using an international standard SNPs)69,70 830 SNP cut-off (7 using split (k=15) (SKA) а Kmer analysis 831 (https://github.com/simonrharris/SKA) (v.1.0), a reference-free pairwise method that 832 compares the entire genome (unlike traditional core-genome based comparisons). Medical 833 records from patients were reviewed for comorbidity and antibiotic prescribing data. Potential 834 associations were assessed through univariate analysis using Pearson's chi-squared test or 835 Fisher's exact test for categorical data, and the Student's *t*-test (parametric) or Wilcoxon Rank 836 Sum test (non-parametric) for continuous data. To determine predictors of daptomycin-837 resistant VREfm, multivariable logistic regression with backward stepwise elimination 838 procedure was used, excluding variables with P>0.10 and re-including variables with P<0.05. 839 Exposure to rifampicin and daptomycin were forced into the models as variables a priori. A P 840 value of <0.05 was considered statistically significant. Cases with missing data (e.g. incomplete 841 medical records data due to inter-hospital transfer) were excluded. Several sensitivity analyses 842 were also performed to assess for independent associations after excluding potential 843 confounders, including analysis with exclusion of variables with <10 outcomes, assessing 844 associations with antimicrobial exposure separately from demographic and comorbidity data, 845 and modifying the rifaximin exposure variable to include a) any prior exposure to rifaximin 846 (including both recent and distant exposure), and b) any prior exposure to rifamycin antibiotics 847 (including rifampicin, rifabutin and rifaximin). The genomic relationships of VREfm isolates were visualised in a maximum-likelihood phylogenetic tree as before, using a core-SNP 848 849 alignment of 12886 sites. The mutations in RpoB were determined using snippy 850 (https://github.com/tseemann/snippy) (v4.4.5) as described.

851 Analysis of patients receiving rifaximin for haematopoietic stem cell transplantation 852 prophylaxis. 853 To examine the potential association between rifaximin exposure and the presence of 854 daptomycin associated *rpoB* substitutions in VREfm independent of underlying chronic liver 855 disease, we analysed isolates collected from patients undergoing haematopoietic stem cell 856 transplantation (HSCT) from a hospital institution in Regensburg, Germany. In this cohort, 857 rifaximin is used for gut decontamination to reduce risk of gastrointestinal graft-versus-host-858 disease, while liver cirrhosis is a contraindication to HSCT. There were 68 patients initially 859 assessed for recent exposure to rifaximin, which was defined as at least a single dose 860 administered within 90 days prior to the isolate collection date. Only a single isolate was 861 retained for testing and analysis from patients who had multiple samples. In this instance, the isolate included was randomised. The isolates underwent WGS using Ion Torrent Next-862 863 Generation sequencing technology (Thermo Fisher) and nanopore (Oxford Nanopore). Patients with isolates that were assessed as genetically clustered with other isolates in the 864 865 cohort and likely represented direct transmission were excluded (as above). Statistical and 866 phylogenetic analyses were undertaken as described above.

867 Ultrahigh-performance liquid chromatography (UHPLC) and mass spectrometry (MS) 868 analyses

869 Cultures of VREfm (n=5) were grown to mid-exponential phase (OD600 = 0.6) and washed in 870 PBS. The protein content for each sample was measured with a Pierce BCA Protein Assay Kit 871 (Thermo Fischer) and normalised to 100 µg. Cells were lysed using Bertin Precellys 24 872 homogenizer set at 6000 rpm for 40 seconds and lipids were subjected to monophasic extraction as described previously⁷². Lipidomic samples were analysed by UHPLC coupled to 873 874 tandem mass spectrometry (MS/MS) employing a Vanguish UHPLC linked to an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA), with separate 875 876 runs in positive and negative ion polarities. Solvent A [60:40 (v:v) acetonitrile/water with 5

mM medronic acid and 10 mM ammonium acetate] and solvent B [90:10 (v:v) isopropanol:acetonitrile with 10 mM ammonium acetate]. 10 μ L of each sample was injected into an Acquity UPLC HSS T3 C18 column (1 x 150 mm, 1.8 μ m; Waters, Milford, MA, USA) at 50 °C at a flow rate of 60 μ L/min for 3 min using 3% solvent B. During separation, the percentage of solvent B was increased from 3% to 70% in 5 min and from 70% to 99% in 16 min. Subsequently, the percentage of solvent B was maintained at 99% for 3 min. Finally, the percentage of solvent B was decreased to 3% in 0.1 min and maintained for 3.9 min.

884 All MS experiments were performed using an electrospray ionization source. The spray 885 voltages were 3.5 kV in positive ionisation-mode and 3.0 kV in negative ionisation-mode. In 886 both polarities, the flow rates of sheath, auxiliary and sweep gases were 25 and 5 and 0 887 arbitrary unit(s), respectively. The ion transfer tube and vaporizer temperatures were 888 maintained at 300 °C and 150 °C, respectively, and the ion funnel RF level was set at 50%. In 889 the positive ionisation-mode from 3 to 24 min, top speed data-dependent scan with a cycle 890 time of 1 s was used. Within each cycle, a full-scan MS-spectra were acquired firstly in the 891 Orbitrap at a mass resolving power of 120,000 (at m/z 200) across an m/z range of 300–2000 892 using quadrupole isolation, an automatic gain control (AGC) target of 4e5 and a maximum 893 injection time of 50 milliseconds, followed by higher-energy collisional dissociation (HCD)-894 MS/MS at a mass resolving power of 15,000 (at m/z 200), a normalised collision energy (NCE) 895 of 27% at positive mode and 30% at negative mode, an m/z isolation window of 1, a maximum 896 injection time of 35 milliseconds and an AGC target of 5e4.

897 Identification and quantification of lipids and statistical analysis

LC-MS/MS data was searched through MS Dial 4.90. The mass accuracy settings were 0.005 Da and 0.025 Da for MS1 and MS2. The minimum peak height was 50000 and mass slice width was 0.05 Da. The identification score cut off was 80%. In positive ionisation mode, [M+H]+, 901 [M+NH4]+ and [M+H-H2O]+ were selected as ion forms. In negative ionisation mode, [M-H]-902 and [M+CH3COO]- were selected as ion forms. All lipid classes available were selected for the 903 search. PC, Lys-PC, DG, TG, CE, SM were identified and quantified from positive ionisation 904 mode while PE, LPE, PS, LPS, PG, LPG, PI, LPI, PA, LPA, Cer, CL were identified and quantified in 905 negative ionisation mode. The retention time tolerance for alignment was 0.1 min. Lipids with 906 maximum intensity less than 5-fold of average intensity in blank were removed. All other 907 settings were default. All lipid LC-MS features were manually inspected and re-integrated 908 when needed. These four types of lipids, 1) lipids with only sum composition except SM, 2) 909 lipid identification due to peak tailing, 3) retention time outliner within each lipid class, 4) LPA 910 and PA artefacts generated by in-source fragmentation of LPS and PS were also removed. The 911 shorthand notation used for lipid classification and structural representation follows the 912 nomenclature proposed previously⁷³. Relative quantification of the lipid species was achieved 913 using the mass spectrometry intensity of each lipid ion at apex of LC peak and normalized to 914 the protein quantity in each sample.

915 **RNA-seq transcriptomics analysis**

916 Cultures were grown to mid-exponential phase (OD600 = 0.6) and total RNA was extracted 917 using Direct-zol RNA Miniprep kit (Zymo Research) according to manufacturer's instructions. 918 Cells were lysed using Bertin Precellys 24 homogenizer set at 6000 rpm for 40 seconds. 919 Samples were treated with TURBO DNase (Thermo Fisher) followed by clean up with the RNA 920 clean and concentrator kit (Zymo Research) according to manufacturer's instructions. The 921 absence of DNA contamination was checked by PCR and RNA integrity and purity was checked 922 with a Bioanalyser RNA kit (Agilent). Five sequencing libraries from independent RNA 923 extractions were made for each of the VREfm strains using the Stranded Total RNA with Ribo-924 Zero Plus (Illumina) kit and sequenced on a single lane of an Illumina NovaSeq 6000 platform.

925 Raw paired-end TrimGalore reads quality trimmed using were 926 (https://www.bioinformatics.babraham.ac.uk/projects/trim galore/) (v0.6.2). Bases with a 927 quality score <20 and reads shorter than 50bp after trimming were discarded. rRNA was 928 removed by the BBDuk script in BBtools (https://sourceforge.net/projects/bbmap/) (v39.01). 929 The resulting reads were aligned to the Aus0233 reference genome by Bowtie 2^{74} (v2.5.1) 930 using the --no-mixed flag and read counts were generated using htseq-count⁷⁵ (v. 0.12.4) using 931 the options -r pos -t CDS -m union --nonunique none. Differentially expressed genes were 932 detected using Degust (v4.1.1). Genes with log₂(fold change) >1.5 and adjusted p-value < 0.05 933 were considered differentially expressed.

934 **Proteomic analysis**

935 Pelleted snap frozen bacterial cells (OD600 = 0.6) were solubilized in 4% SDS, 100mM Tris pH 936 8.5 by heating them for 10 min at 95 °C. The protein concentrations were assessed by a 937 bicinchoninic acid protein assay (Thermo Fisher Scientific) and 100 µg of each biological 938 replicate prepared for digestion using Micro S-traps (Protifi, USA) according to the 939 manufacturer's instructions. Briefly, samples were reduced with 10mM DTT for 10 mins at 940 95°C and then alkylated with 40mM IAA in the dark for 1 hour. Samples were acidified to 1.2% 941 phosphoric acid and diluted with seven volumes of S-trap wash buffer (90% methanol, 100 942 mM tetraethylammonium bromide pH 7.1) before being loaded onto S-traps and washed 3 943 times with S-trap wash buffer. Samples were then digested with trypsin before being collected by centrifugation after the addition of 100 mM tetraethylammonium bromide, followed by 944 945 0.2% formic acid and then 0.2% formic acid / 50% acetonitrile. Samples were dried and further cleaned up using C18 Stage^{76,77} tips to ensure the removal of any particulate matter. 946

947 C18 enriched proteome samples were re-suspended in 2% acetonitrile (aq) containing 0.01%
948 trifluoroacetic acid (Buffer A*) and separated using a Vanquish Neo UHPLC (Thermo Fisher

949 Scientific) with a single column chromatography set up composed of a ACQUITY UPLC Peptide 950 BEH C18 Column (300Å, 1.7 μm, 1 mm X 100 mm, Waters Corporation) at a flow rate of 50 951 µL/min. Proteome samples were loaded directly on to the ACQUITY column with Buffer A 952 (0.1% formic acid, 2% DMSO) coupled directly to an Orbitrap 480[™] mass spectrometer 953 (Thermo Fisher Scientific) and the buffer composition altered from 2% Buffer B (0.1% formic 954 acid, 77.9% acetonitrile, 2% DMSO) to 26% B over 70 minutes, then from 26% B to 99% B over 955 2 minutes and then was held at 99% B for 1.5 minutes. The mass spectrometer was operated 956 in a data-independent mode automatically switching between the acquisition of a single 957 Orbitrap MS scan (370-1050 m/z, maximal injection time of 50 ms, an AGC set to a maximum 958 of 300% and mass resolving power of 120,000 (at m/z 200) and the collection of 16.5 m/z DIA 959 windows between 375 and 1015 m/z (200-2000 m/z, NCE 32%, maximal injection time of 54 960 ms, an AGC set to 1000% and a mass resolving power of 30,000 (at m/z 200). Identification 961 and label free quantitation (LFQ) analysis were accomplished using Spectronaut (Biognosys, 962 Switzerland) versions 16 (16.0.220606.53000) using directDIA based analysis with minor 963 modifications: Protein LFQ method set to MaxLFQ, single hit proteins excluded, and 964 imputation disabled. Data was searched against the *E. faecium* Aus0004 proteome⁴⁶ (Uniprot 965 accession: UP000007591) with Carbamidomethyl (C) allowed as a fixed modification and 966 Acetyl (Protein N-term) as well as Oxidation (M) allowed as variable modifications. Data 967 outputs from Spectronaut were processed using Perseus (version 1.6.0.7)⁷⁸ with missing values imputed based on the total observed protein intensities with a range of 0.3 σ and a 968 969 downshift of 1.8 σ. Statistical analysis was undertaken in Perseus using two-tailed unpaired t-970 tests and ANOVAs. Proteins with $\log_2(fold change) > 1$ and adjusted p-value < 0.05 were 971 considered differentially expressed.

972 Computational modelling

In predicting the potential effects of substitutions Q473L, G482D, H486Y, and S491F, the full E. 973 974 faecium DNA-dependent RNA polymerase was initially modelled using Advanced Homology 975 Modelling in Maestro (Schrodinger suite). BLAST-pdb was used to identify the *M. tuberculosis* homologue (PDB: 5UHC)³⁶ as the template, as it had the best sequence identities across all 976 977 RNA polymerase subunits. Modelling was carried out based on consensus between sequence 978 alignments from MAFFT-DASH⁷⁹, T-COFFEE⁸⁰, and Clustal-W⁸¹ (within Maestro), which were 979 manually optimised to minimise sequence gaps. The final RNA polymerase model, bound to 980 rifampicin and the DNA replication fork was next subjected to loop refinement and 981 minimisation, and iteratively assessed for model guality within Maestro.

The modelled structure was used as input within *in silico* biophysical predictors Dynamut2⁸², 982 mmCSM-lig (https://biosig.lab.uq.edu.au/mmcsm lig/), mmCSM-NA⁸³, and mCSM-PPI2⁸³, 983 which predicted the effects of mutations Q473L, G482D, H486Y, and S491F on β -subunit 984 985 stability, and affinities to rifampicin, nucleic acids within the replication fork, and other RNA 986 polymerase subunits, respectively. During interpretation, all values were collectively 987 considered to assess potential protein-level implications to wild type function. In doing so, the 988 affinity values for mutations located beyond 12 Å of the binding partner were presumed 989 negligible.

990 Estimation of Zeta potential

The Zeta potential was measured on cells grown to exponential phase (OD600 = 0.6) and washed in PBS. The Zeta potential measurements were performed in PBS to minimise influence of pH. Each experiment was carried out under identical experiment conditions (n=5), 25°C with two minutes of equilibration. The Zeta potential was measured with a Zetasizer (Malvern, UK).

996 Determination of cell-associated daptomycin with BoDipy labelling

997 BoDipy fluorescent dye (4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-S-Indacene) 998 (Invitrogen) was used to label daptomycin with minor modifications⁸⁴. Briefly, 50 µL 999 daptomycin (50 mg mL⁻¹) was mixed with 100 µL BoDipy (10 mg mL⁻¹) and was made up to a 1000 final volume of 1 mL in 200 mM sodium bicarbonate (pH 8.5). The reaction was incubated for 1001 1 hour at 37°C and unbound BoDipy was removed by dialysis at 4°C using a Slide-A-Lyzer 1002 cassette (Thermo Scientific), with a 2.0 kDa cut-off, as per manufacturer's instructions. The 1003 antibiotic activity of BoDipy-daptomycin was confirmed by BMD (described above). To 1004 measure cell-associated DAP, cultures were grown to exponential phase (OD600 = 0.6) 50 mg 1005 L^{-1} CaCl₂. Each culture was incubated with BoDipy-daptomycin in darkness (10 minutes) and 1006 washed to remove unbound BoDipy- daptomycin. The amount of bound BoDipy- daptomycin 1007 was measured with excitation at 490 nm and emission at 528 nm using an Ensight microplate 1008 reader (PerkinElmer). Biological replicates (n=5) were completed on separate days.

1009 Data visualisation and statistics

1010 All figures were generated in R (v4.0.3, https://www.r-project.org/) using tidyverse (v.1.3.1),

1011 patchwork (v.1.1.1), and ggnewscale (v.0.4.5). Statistical analyses were performed using R

1012 (v4.0.3, https://www.r-project.org/) and GraphPad Prism (v9.3.1) software packages. Specific

- 1013 tests are provided together with each corresponding result in the text.
- 1014 Ethics approval
- 1015 Data were obtained from medical records with approval from the local Human Research Ethics
- 1016 Committee (HREC/92972/Austin-2023).
- 1017 Competing Interests
- 1018 The authors declare no competing interests.
- 1019 Acknowledgements

1020 This work was supported by the National Health and Medical Research Council (NHMRC) of 1021 Australia (GNT1185213 and GNT1160745). BPH is supported by an NHMRC Investigator Grant 1022 (GNT1196103). JCK is supported by an NHMRC Early Career Fellowship (GNT1142613). AMT 1023 and NLS are supported by an Australian Government Research Training Program scholarship. 1024 DJI is supported by an NHMRC Investigator Grant (GNT1195210). SD is supported by the 1025 Australian Research Council (DE190100805). The Controlling Superbugs study was supported by the Melbourne Genomics Health Alliance (funded by the State Government of Victoria, 1026 1027 Department of Health and Human Services, and the 10 member organizations). NES is 1028 supported by an Australian Research Council Future Fellowship (FT200100270) and an ARC 1029 Discovery Project Grant (DP210100362). We thank the Melbourne Mass Spectrometry and 1030 Proteomics Facility of The Bio21 Molecular Science and Biotechnology Institute for access to 1031 MS instrumentation and staff within the Microbiological Diagnostic Unit Public Health 1032 Laboratory for technical assistance with antimicrobial susceptibility testing and whole genome 1033 sequencing.

1034 Author Contributions

GPC, BPH, and CLG conceived and planned the experiments. AMT, LL, IRM, DJI, SD, SP, NI, LKS, GR, SN, NES, BAE, DA, and GPC performed the planned experiments. JCK, NEH, BK, DW, AG and EH provided access to necessary patient metadata and JCK and SV preformed statistical analyses in the patient cohort studies. AH, JYHL, NLS, TPS, TS, BPH, EH and JCK provided critical clinical or bioinformatic insights for the study. AMT, CLG, and GPC co-wrote the manuscript with critical feedback and input from all authors.

- 1041 Corresponding Authors
- 1042 Correspondence to Glen Carter or Benjamin Howden.
- 1043 Data Availability

1044 The WGS and RNA sequencing data presented in the study are deposited under Bioprojects 1045 PRJNA565795, PRJNA433676, PRJNA856406, and PRJNA856406. The mass spectrometry 1046 proteomics data has been deposited in the Proteome Xchange Consortium via the PRIDE repository⁸⁵ 1047 identifier: PXD039832 partner with (Username: the data set 1048 (Username: reviewer_pxd039832@ebi.ac.uk Password: fwjEy0ah) and PXD039831 1049 reviewer pxd039831@ebi.ac.uk Password: 9SrIrmu8).

1051 References

- 1052 1. Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a
- 1053 systematic analysis. *The Lancet* **399**, 629–655 (2022).
- 1054 2. Bylicka-Szczepanowska, E. & Korzeniewski, K. Asymptomatic Malaria Infections in the
- 1055 Time of COVID-19 Pandemic: Experience from the Central African Republic. Int. J.
- 1056 Environ. Res. Public. Health **19**, 3544 (2022).
- 1057 3. Global HIV & AIDS statistics Fact sheet. https://www.unaids.org/en/resources/fact-
- 1058 sheet.
- 1059 4. GBD 2019 Collaborators. Global mortality from dementia: Application of a new method
- and results from the Global Burden of Disease Study 2019. *Alzheimers Dement. N. Y. N* **7**,

1061 e12200 (2021).

- 1062 5. Arias, C. A. & Murray, B. E. The rise of the *Enterococcus*: beyond vancomycin resistance.
 1063 *Nat. Rev. Microbiol.* 10, 266–278 (2012).
- 1064 6. Top, J., Willems, R. & Bonten, M. Emergence of CC17 Enterococcus faecium: from
- 1065 commensal to hospital-adapted pathogen. *FEMS Immunol. Med. Microbiol.* 52, 297–308
 1066 (2008).
- 1067 7. Arthur, M. & Courvalin, P. Genetics and mechanisms of glycopeptide resistance in
- 1068 enterococci. Antimicrob. Agents Chemother. **37**, 1563–1571 (1993).
- 1069 8. De Oliveira, D. M. P. *et al.* Antimicrobial Resistance in ESKAPE Pathogens. *Clin. Microbiol.*
- 1070 *Rev.* **33**, e00181-19 (2020).
- 1071 9. Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO
- 1072 priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–

1073 327 (2018).

- 1074 10. Montero, C. I., Stock, F. & Murray, P. R. Mechanisms of Resistance to Daptomycin in
- 1075 Enterococcus faecium. Antimicrob. Agents Chemother. (2008) doi:10.1128/AAC.00774-
- 1076 07.
- 1077 11. Diaz, L. et al. Whole-Genome Analyses of Enterococcus faecium Isolates with Diverse
- 1078 Daptomycin MICs. Antimicrob. Agents Chemother. (2014).
- 1079 12. Lellek, H. et al. Emergence of daptomycin non-susceptibility in colonizing vancomycin-
- 1080 resistant *Enterococcus faecium* isolates during daptomycin therapy. *Int. J. Med.*
- 1081 *Microbiol.* **305**, 902–909 (2015).
- 1082 13. Kelesidis, T., Tewhey, R. & Humphries, R. M. Evolution of high-level daptomycin
- 1083 resistance in *Enterococcus faecium* during daptomycin therapy is associated with limited
- 1084 mutations in the bacterial genome. J. Antimicrob. Chemother. 68, 1926–1928 (2013).
- 1085 14. Werth, B. J. et al. Defining Daptomycin Resistance Prevention Exposures in Vancomycin-
- 1086 Resistant Enterococcus faecium and E. faecalis. Antimicrob. Agents Chemother. 58,
- 1087 5253–5261 (2014).
- 1088 15. Turner, A. M., Lee, J. Y. H., Gorrie, C. L., Howden, B. P. & Carter, G. P. Genomic Insights
- 1089 Into Last-Line Antimicrobial Resistance in Multidrug-Resistant *Staphylococcus* and
- 1090 Vancomycin-Resistant *Enterococcus*. Front. Microbiol. **12**, (2021).
- 1091 16. Li, L. et al. Daptomycin Resistance Occurs Predominantly in vanA-Type Vancomycin-
- 1092 Resistant *Enterococcus faecium* in Australasia and Is Associated With Heterogeneous
- and Novel Mutations. *Front. Microbiol.* **12**, 749935 (2021).
- 1094 17. Bass, N. M. *et al.* Rifaximin Treatment in Hepatic Encephalopathy. *N. Engl. J. Med.* 362,
 1095 1071–1081 (2010).
- 1096 18. Shayto, R. H., Abou Mrad, R. & Sharara, A. I. Use of rifaximin in gastrointestinal and liver
 1097 diseases. *World J. Gastroenterol.* 22, 6638–6651 (2016).

- 1098 19. Sherry, N. L. et al. Pilot study of a combined genomic and epidemiologic surveillance
- 1099 program for hospital-acquired multidrug-resistant pathogens across multiple hospital
- 1100 networks in Australia. *Infect. Control Hosp. Epidemiol.* **42**, 573–581 (2021).
- 1101 20. Gorrie, C. L. et al. Key parameters for genomics-based real-time detection and tracking
- 1102 of multidrug-resistant bacteria: a systematic analysis. *Lancet Microbe* **2**, e575–e583
- 1103 (2021).
- 1104 21. Miller, W. R., Bayer, A. S. & Arias, C. A. Mechanism of Action and Resistance to
- 1105 Daptomycin in *Staphylococcus aureus* and Enterococci. *Cold Spring Harb. Perspect. Med.*
- **6**, a026997 (2016).
- 1107 22. Merker, M. et al. Transcontinental spread and evolution of Mycobacterium tuberculosis
- 1108 W148 European/Russian clade toward extensively drug resistant tuberculosis. *Nat.*
- 1109 *Commun.* **13**, 5105 (2022).
- 1110 23. Brandis, G., Wrande, M., Liljas, L. & Hughes, D. Fitness-compensatory mutations in
- 1111 rifampicin-resistant RNA polymerase. *Mol. Microbiol.* **85**, 142–151 (2012).
- 1112 24. Goldstein, B. P. Resistance to rifampicin: a review. *J. Antibiot. (Tokyo)* 67, 625–630
 1113 (2014).
- 1114 25. Rios, R. et al. Genomic Epidemiology of Vancomycin-Resistant Enterococcus faecium
- 1115 (VREfm) in Latin America: Revisiting The Global VRE Population Structure. *Sci. Rep.* 10,
 1116 5636 (2020).
- 1117 26. Duchêne, S. et al. Genome-scale rates of evolutionary change in bacteria. Microb.
- 1118 *Genomics* **2**, e000094 (2016).
- 1119 27. Lebreton, F. et al. Emergence of Epidemic Multidrug-Resistant Enterococcus faecium
- from Animal and Commensal Strains. *mBio* **4**, e00534-13.

- 1121 28. Raven, K. E. et al. A decade of genomic history for healthcare-associated Enterococcus
- 1122 *faecium* in the United Kingdom and Ireland. *Genome Res.* **26**, 1388–1396 (2016).
- 1123 29. Sensi, P. History of the Development of Rifampin. *Rev. Infect. Dis.* 5, S402–S406 (1983).
- 1124 30. Goel, A., Rahim, U., Nguyen, L. H., Stave, C. & Nguyen, M. H. Systematic review with
- 1125 meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.
- 1126 Aliment. Pharmacol. Ther. **46**, 1029–1036 (2017).
- 1127 31. Lee, R. A. et al. Daptomycin-Resistant Enterococcus Bacteremia Is Associated With Prior
- 1128 Daptomycin Use and Increased Mortality After Liver Transplantation. *Open Forum Infect.*
- 1129 *Dis.* **9**, ofab659 (2022).
- 1130 32. Lee, R. S. et al. The changing landscape of vancomycin-resistant Enterococcus faecium in
- Australia: a population-level genomic study. *J. Antimicrob. Chemother.* **73**, 3268–3278
 (2018).
- 1133 33. Weber, D. et al. Rifaximin preserves intestinal microbiota balance in patients undergoing
- allogeneic stem cell transplantation. *Bone Marrow Transplant.* **51**, 1087–1092 (2016).
- 1135 34. Taur, Y. et al. Intestinal Domination and the Risk of Bacteremia in Patients Undergoing
- 1136 Allogeneic Hematopoietic Stem Cell Transplantation. *Clin. Infect. Dis.* 55, 905–914
- 1137 (2012).
- 1138 35. Morley, V. J. et al. An adjunctive therapy administered with an antibiotic prevents
- 1139 enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen. *eLife* 9,
- 1140 e58147 (2020).
- 1141 36. Lin, W. et al. Structural Basis of Mycobacterium tuberculosis Transcription and
- 1142 Transcription Inhibition. *Mol. Cell* **66**, 169-179.e8 (2017).

- 1143 37. Portelli, S., Phelan, J. E., Ascher, D. B., Clark, T. G. & Furnham, N. Understanding
- 1144 molecular consequences of putative drug resistant mutations in *Mycobacterium*
- 1145 *tuberculosis. Sci. Rep.* **8**, 15356 (2018).
- 1146 38. Bender, J. K. et al. Update on prevalence and mechanisms of resistance to linezolid,
- 1147 tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature.
- 1148 Drug Resist. Updat. **40**, 25–39 (2018).
- 1149 39. Tran, T. T. et al. Whole-Genome Analysis of a Daptomycin-Susceptible Enterococcus
- 1150 *faecium* Strain and Its Daptomycin-Resistant Variant Arising during Therapy. *Antimicrob.*
- 1151 Agents Chemother. **57**, 261–268 (2013).
- 1152 40. Guérillot, R. *et al.* Convergent Evolution Driven by Rifampin Exacerbates the Global
- 1153 Burden of Drug-Resistant *Staphylococcus aureus*. *mSphere* **3**, e00550-17.
- 1154 41. Bæk, K. T. et al. Stepwise Decrease in Daptomycin Susceptibility in Clinical
- 1155 Staphylococcus aureus Isolates Associated with an Initial Mutation in rpoB and a
- 1156 Compensatory Inactivation of the *clpX* Gene. *Antimicrob. Agents Chemother.* (2015).
- 1157 42. Cui, L. et al. An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and
- 1158 Vancomycin in *Staphylococcus aureus*. *Antimicrob*. *Agents Chemother*. (2010)
- 1159 doi:10.1128/AAC.00437-10.
- 43. Snyder, E. E. *et al.* PATRIC: The VBI PathoSystems Resource Integration Center. *Nucleic*Acids Res. 35, D401–D406 (2007).
- 1162 44. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2.
- 1163 Genome Biol. 20, 257 (2019).
- 1164 45. Humphries, R. M. The New, New Daptomycin Breakpoint for *Enterococcus* spp. J. Clin.
- 1165 *Microbiol.* **57**, e00600-19.

- 1166 46. Lam, M. M. et al. Comparative analysis of the complete genome of an epidemic hospital
- 1167 sequence type 203 clone of vancomycin-resistant *Enterococcus faecium*. *BMC Genomics*
- **1168 14**, 595 (2013).
- 1169 47. Bankevich, A. et al. SPAdes: A New Genome Assembly Algorithm and Its Applications to
- 1170 Single-Cell Sequencing. J. Comput. Biol. **19**, 455–477 (2012).
- 1171 48. Homan, W. L. et al. Multilocus sequence typing scheme for Enterococcus faecium. J. Clin.
- 1172 *Microbiol.* **40**, 1963–1971 (2002).
- 1173 49. Minh, B. Q. et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic
- 1174 Inference in the Genomic Era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020).
- 1175 50. Schliep, K. P. phangorn: phylogenetic analysis in R. *Bioinformatics* **27**, 592–593 (2011).
- 1176 51. Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and
- 1177 evolutionary analyses in R. *Bioinformatics* **35**, 526–528 (2019).
- 1178 52. Yu, G., Smith, D. K., Zhu, H., Guan, Y. & Lam, T. T.-Y. ggtree: an r package for visualization
- and annotation of phylogenetic trees with their covariates and other associated data.
- 1180 *Methods Ecol. Evol.* **8**, 28–36 (2017).
- 1181 53. Sherry, N. L. et al. An ISO-certified genomics workflow for identification and surveillance
- 1182 of antimicrobial resistance. *Nat. Commun.* **14**, 60 (2023).
- 1183 54. Crispell, J., Balaz, D. & Gordon, S. V. HomoplasyFinder: a simple tool to identify
- 1184 homoplasies on a phylogeny. *Microb. Genomics* **5**, e000245 (2019).
- 1185 55. Lees, J. A., Galardini, M., Bentley, S. D., Weiser, J. N. & Corander, J. pyseer: a
- 1186 comprehensive tool for microbial pangenome-wide association studies. *Bioinformatics*
- **34**, 4310–4312 (2018).
- 1188 56. de Been, M. et al. Core Genome Multilocus Sequence Typing Scheme for High-
- 1189 Resolution Typing of *Enterococcus faecium*. J. Clin. Microbiol. **53**, 3788–3797 (2015).

- 1190 57. Silva, M. *et al.* chewBBACA: A complete suite for gene-by-gene schema creation and
- 1191 strain identification. *Microb. Genomics* **4**, e000166 (2018).
- 1192 58. Croucher, N. J. et al. Rapid phylogenetic analysis of large samples of recombinant
- bacterial whole genome sequences using Gubbins. *Nucleic Acids Res.* **43**, e15 (2015).
- 1194 59. Nguyen, L.-T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: A Fast and
- 1195 Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. *Mol.*
- 1196 *Biol. Evol.* **32**, 268–274 (2015).
- 1197 60. Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal
- 1198 structure of heterochronous sequences using TempEst (formerly Path-O-Gen). Virus
- 1199 *Evol.* **2**, vew007 (2016).
- 1200 61. Suchard, M. A. *et al.* Bayesian phylogenetic and phylodynamic data integration using
 1201 BEAST 1.10. *Virus Evol.* 4, vey016 (2018).
- 1202 62. Minin, V. N. & Suchard, M. A. Counting labeled transitions in continuous-time Markov
 1203 models of evolution. *J. Math. Biol.* 56, 391–412 (2008).
- 1204 63. Minin, V. N. & Suchard, M. A. Fast, accurate and simulation-free stochastic mapping.
 1205 *Philos. Trans. R. Soc. B Biol. Sci.* **363**, 3985–3995 (2008).
- 1206 64. Monk, I. R., Tree, J. J., Howden, B. P., Stinear, T. P. & Foster, T. J. Complete Bypass of
- 1207 Restriction Systems for Major *Staphylococcus aureus* Lineages. *mBio* **6**, e00308-15.
- 1208 65. Zhang, Y., Werling, U. & Edelmann, W. Seamless Ligation Cloning Extract (SLiCE) Cloning
- 1209 Method. in DNA Cloning and Assembly Methods (eds. Valla, S. & Lale, R.) 235–244
- 1210 (Humana Press, Totowa, NJ, 2014). doi:10.1007/978-1-62703-764-8_16.
- 1211 66. Pidot, S. J. et al. Increasing tolerance of hospital Enterococcus faecium to handwash
- 1212 alcohols. *Sci. Transl. Med.* **10**, eaar6115 (2018).

- 1213 67. Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and
- 1214 human. J. Basic Clin. Pharm. **7**, 27–31 (2016).
- 1215 68. Heine, H. S., Bassett, J., Miller, L., Purcell, B. K. & Byrne, W. R. Efficacy of Daptomycin
- against *Bacillus anthracis* in a Murine Model of Anthrax Spore Inhalation. *Antimicrob*.
- 1217 Agents Chemother. **54**, 4471–4473 (2010).
- 1218 69. Higgs, C. et al. Optimising genomic approaches for identifying vancomycin-resistant
- 1219 *Enterococcus faecium* transmission in healthcare settings. *Nat. Commun.* **13**, 509 (2022).
- 1220 70. Maechler, F. *et al.* Split k-mer analysis compared to cgMLST and SNP-based core genome
- 1221 analysis for detecting transmission of vancomycin-resistant enterococci: results from
- 1222 routine outbreak analyses across different hospitals and hospitals networks in Berlin,
- 1223 Germany. *Microb. Genomics* **9**, 000937 (2023).
- 1224 71. Liese, J. et al. Expansion of Vancomycin-Resistant Enterococcus faecium in an Academic
- 1225 Tertiary Hospital in Southwest Germany: a Large-Scale Whole-Genome-Based Outbreak
- 1226 Investigation. *Antimicrob. Agents Chemother.* **63**, e01978-18 (2019).
- 1227 72. Kralj, T. et al. Multi-Omic Analysis to Characterize Metabolic Adaptation of the E. coli
- 1228 Lipidome in Response to Environmental Stress. *Metabolites* **12**, (2022).
- 1229 73. Liebisch, G. et al. Update on LIPID MAPS classification, nomenclature, and shorthand
- 1230 notation for MS-derived lipid structures. J. Lipid Res. 61, 1539–1555 (2020).
- 1231 74. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods
- **9**, 357–359 (2012).
- 1233 75. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-
- 1234 throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).

- 1235 76. Rappsilber, J., Ishihama, Y. & Mann, M. Stop and Go Extraction Tips for Matrix-Assisted
- 1236 Laser Desorption/Ionization, Nanoelectrospray, and LC/MS Sample Pretreatment in
- 1237 Proteomics. Anal. Chem. **75**, 663–670 (2003).
- 1238 77. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-
- 1239 fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2,
- 1240 1896–1906 (2007).
- 1241 78. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized
- 1242 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat.*
- 1243 Biotechnol. 26, 1367–1372 (2008).
- 1244 79. Rozewicki, J., Li, S., Amada, K. M., Standley, D. M. & Katoh, K. MAFFT-DASH: integrated
- 1245 protein sequence and structural alignment. *Nucleic Acids Res.* **47**, W5–W10 (2019).
- 1246 80. Magis, C. *et al.* T-Coffee: Tree-based consistency objective function for alignment

1247 evaluation. *Methods Mol. Biol. Clifton NJ* **1079**, 117–129 (2014).

- 1248 81. Higgins, D. G. & Sharp, P. M. CLUSTAL: a package for performing multiple sequence
- 1249 alignment on a microcomputer. *Gene* **73**, 237–244 (1988).
- 1250 82. Rodrigues, C. H. M., Pires, D. E. V. & Ascher, D. B. DynaMut2: Assessing changes in
- 1251 stability and flexibility upon single and multiple point missense mutations. *Protein Sci.*
- 1252 Publ. Protein Soc. **30**, 60–69 (2021).
- 1253 83. Nguyen, T. B., Myung, Y., de Sá, A. G. C., Pires, D. E. V. & Ascher, D. B. mmCSM-NA:
- 1254 accurately predicting effects of single and multiple mutations on protein-nucleic acid
- 1255 binding affinity. *NAR Genomics Bioinforma*. **3**, lqab109 (2021).
- 1256 84. Pader, V. et al. Staphylococcus aureus inactivates daptomycin by releasing membrane
- 1257 phospholipids. *Nat. Microbiol.* **2**, 1–8 (2016).

- 1258 85. Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass
- 1259 spectrometry-based proteomics evidences. *Nucleic Acids Res.* **50**, D543–D552 (2022).



1262 Figure 1. A. Manhattan plot of 10,530 variants, displayed by position on the reference genome 1263 and significance association with daptomycin resistance (univariate analysis using a linear 1264 mixed model). The dashed line shows the Bonferroni-corrected significance threshold. B. 1265 Percentage of daptomycin-resistant strains for each mutation within RpoB. The mutations 1266 within the rifampicin resistance determining region (RRDR) are shown in bold. Mutations 1267 coloured in red were associated with daptomycin resistance. The total number of strains 1268 containing each mutation is shown above each bar. C. Maximum-likelihood core-SNP-based 1269 phylogeny of clinical VREfm (n=1000) inferred from 6,574 SNPs, demonstrating the presence 1270 of RpoB mutations in daptomycin-resistant isolates. Overlaid are the results of in silico multi-1271 locus sequence type (MLST), daptomycin phenotypic testing, and mutations associated with 1272 daptomycin resistance in RpoB. In the first circle, ST is not shown for uncommon STs ($n \le 5$). 1273 The scale bar indicates number of nucleotide substitutions per site (top), with an 1274 approximation of SNP distance (in parentheses). **D.** Rifampicin susceptibility testing results for 1275 the WT and isogenic rpoB mutants and complement strains (designated with -C) (n=3). E. 1276 Daptomycin susceptibility testing results for the WT and isogenic rpoB mutants and 1277 complemented strains (designated with -C) (n=3). The MIC for each strain is shown without 1278 error bars since there was no variation between the independent biological replicates.



1280 Figure 2. A. Map of 4,476 VREfm genomes included in this study. Circle size corresponds to 1281 total number of genomes (binned into categories), and colour corresponds to region of 1282 isolation. Country coordinates used are the country centroid position. B. The frequency of 1283 various RpoB mutations within the rifampicin resistance determining region (RRDR) in 4,476 1284 VREfm genomes, sampled from 43 MLSTs. Bars are coloured by the number of isolates from 1285 each region of isolation containing the mutation. The identified daptomycin resistance associated mutations are coloured in red. C. Maximum-likelihood, core-SNP-based phylogeny 1286 1287 for 4,476 VREfm inferred from 9,277 core-genome SNPs, demonstrating the presence of the 1288 S491F RpoB mutation in international VREfm. Overlaid is the region of isolation for each strain 1289 and the presence of the S491F mutation. The coloured branches indicate the three VREfm 1290 clusters identified with cgMLST used as input for Bayesian evolutionary analyses. The scale 1291 bar indicates number of nucleotide substitutions per site (top), with an approximation of SNP 1292 distance (in parentheses). D. Bayesian phylodynamic analyses showing the maximum-clade 1293 credibility (MCC) trees of the three VREfm clusters with the timing of emergence for each 1294 lineage. The median substitution rate was similar for Cluster 1 and Cluster 2, at 9.7x10-7 [95% 1295 highest posterior density (HPD) 6.88x10-7 - 1.24x10-6] and 1.25x10-6 (95% HPD 7.68x10-7 -1296 1.74x10-6) respectively, but slightly faster for Cluster 3 at 3.86x10-6 (95% HPD 2.23x10-6 – 1297 5.69x10-6). Cluster 1 (n=219) was inferred from a core alignment of 1,869,554 bp containing 1298 329 SNP sites; Cluster 2 (n=85) was inferred from an alignment of 1,524,024 bp containing 541 1299 SNP sites; and Cluster 3 (n=68) was inferred from an alignment of 1,860,780 bp containing 764 1300 SNP sites. The time in years is given on the x axis. The presence of the S491F RpoB trait for 1301 each isolate is shown in purple. Overlaid onto the MCC trees is the first instance of FDA 1302 approval for rifaximin (2004) and for hepatic encephalopathy (HE) (2010). E. Violin plots for 1303 the most recent common ancestor (MCRA) for each cluster, representing when the RpoB

- 1304 S491F mutation first emerged, with 95% HPD intervals 2006 (HPD 1993 2012) for Cluster
- 1305 1, 2000 (HPD 1989 2008) for Cluster 2, and 2004 (HPD 2001 2010) for Cluster 3. Overlaid
- 1306 onto violin plots is the FDA approval date for rifaximin (2004).

A

-5



Patient group	
Control	Rifaximin

1308

Figure 3. A. Maximum-likelihood, core-SNP-based phylogeny for VREfm inferred from 14,420 core-genome SNPs, demonstrating which isolates were from the "control" or "rifaximin" groups. The scale bar indicates number of nucleotide substitutions per site. **B.** Summary of the percentage of VREfm with any *rpoB* SNP, daptomycin (DAP)-associated *rpoB* SNP (S491F, G482D and H486Y), or DAP resistance in patients in the "control" or "rifaximin" groups. Data was analysed using a Fisher's exact test.



1319 Figure 4. A. Timeline of the mouse experiment. VREfm-colonised mice (n=5 for vehicle, n=10 1320 for rifampicin, n=10 for rifaximin, n=10 for daptomycin) received a human-equivalent dose of 1321 vehicle, rifampicin, or rifaximin (twice per day for rifaximin) for 7 days by oral gavage or 1322 subcutaneous injection with daptomycin for 7 days. CRO=ceftriaxone; DAP=daptomycin; 1323 RIFAX=rifaximin; RIF=rifampicin. Figure to scale. B. Percentage of total mice with rifampicin-1324 resistant VREfm strains C. or daptomycin-resistant VREfm strains after 7 days of antibiotic 1325 treatment. **D.** Percentage of VREfm from each mouse (n=50 colonies per mouse) that were 1326 resistant to rifampicin E. or daptomycin after 7 days of antibiotic treatment. Points represent 1327 an individual mouse. Percentage was calculated from rifampicin or daptomycin MIC values (either resistant or susceptible) from 50 VREfm colonies isolated from each mouse. Boxes 1328 1329 represent the median and interquartile range for each group. F. Overview of the RpoB 1330 mutations identified in the rifampicin-resistant colonies. Each point represents a single colony. 1331 Isolates are separated by each RpoB mutation and grouped into either daptomycin-1332 susceptible or daptomycin-resistant. The RpoB mutations coloured in red had an association 1333 with daptomycin resistance; n values represent the number of isolates containing each 1334 mutation for rifaximin and rifampicin, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, 1335 ****P<0.0001; unpaired t-test (vehicle versus rifampicin or vehicle versus rifaximin and 1336 rifampicin verses daptomycin or rifaximin verses daptomycin).



1338 Figure 5. A. Principal-component analysis denoting segregation of the total lipid classes 1339 obtained for the WT and RpoB mutants. B to E. The lipid species differentially produced by the 1340 WT and RpoB mutants are showed as normalised abundance (intensity/total protein). Bars 1341 represent the median value and error bars represent the SEM (n=5). Data was analysed with 1342 a Two-way ANOVA (WT versus RpoB mutant) F. Intersection between RNAseq and proteomics 1343 analyses displayed as an UpSet plot (n=5 for RNAseq and n=5 for proteomics). RNA seq 1344 significance (FDR<0.05, $\log_2 FC > 1$ or $\log_2 FC < -1$) and proteomics significance (adjusted p-1345 value<0.05, $\log_2 FC > 1$ or $\log_2 FC < -1$). **G.** Heatmaps displaying the 26 significantly, differentially 1346 expressed loci identified in both RNA seg and proteomics. The fold-change value for RNAseg is shown. H. Daptomycin susceptibility testing results for the WT and *rpoB* backgrounds with 1347 1348 prdR, prdA, or prdB deleted (n=3). The MIC for each strain is shown without error bars since 1349 no variation between independent biological replicate was observed. ns not significant, *P < 1350 0.05, ***P* < 0.01, ****P* < 0.001, *****P*<0.0001.





1353 Figure 6. A. Principal-component analysis denoting segregation of the total lipid classes 1354 obtained for the WT, S491F mutant, WT empty vector (EV), and WT^{prdR}. B and C. The lipid 1355 species differentially produced by the WT, S491F mutant, WT EV, and WT^{prdR} are showed as 1356 normalised abundance (intensity/total protein). Bars represent the median value and error bars represent the SEM (n=5). Data was analysed with a Two-way ANOVA (WT versus RpoB 1357 1358 mutant and WT EV versus WT^{prdR}). **D.** Lipid species differentially produced by the ST203 RpoB 1359 S491F clinical strain pair, showed as normalised abundance (intensity/total protein). The dots 1360 represent the median value (n=5). Data was analysed with a Two-way ANOVA (ST203 DAP-S 1361 versus ST203 DAP-R). Lipid species with a significant difference are denoted. E. Zeta potential (measured in mV). Points represent each biological replicate (n=3) and lines represent the 1362 1363 median and interguartile range. Data was analysed with a Two-way ANOVA (WT versus RpoB 1364 mutant and WT EV versus WT^{prdR}). F. Binding of BoDIPY-DAP, represented as relative 1365 fluorescence units (RFU). Points represent each biological replicate (n=5) and lines represent 1366 the median and interguartile range. Data was analysed with a Two-way ANOVA (WT versus RpoB mutant and WT EV versus WT^{prdR}). ns not significant, *P < 0.05, **P < 0.01, ***P < 0.001, 1367 *****P*<0.0001. 1368

1369